

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:12:59

First Dose M/F: NA / NA

Lab: NCTR

C Number:	C00602F
Lock Date:	Not Entered.
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both
PWG Approval Date	NONE

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:12:59

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	2	4	3	10	9	4
Natural Death	16	13	14	22	6	10
Survivors						
Moribund		4	1	1	1	1
Natural Death	3	1	4	7		3
Terminal Sacrifice	27	26	26	8	32	30
Animals Examined Microscopically	48	48	47	48	48	48
ALIMENTARY SYSTEM						
Esophagus	(47)	(47)	(46)	(46)	(48)	(48)
Gallbladder	(35)	(38)	(36)	(23)	(39)	(41)
Concretion	1 (3%)					
Cyst						1 (2%)
Epithelium, Cytoplasmic Alteration			1 (3%)			
Infiltration Cellular, Lymphocytic	2 (6%)					
Inflammation, Acute		2 (5%)	2 (6%)			1 (2%)
Inflammation, Chronic						
Inflammation, Subacute						
Mucosa, Cyst						
Pigmentation						
Intestine Large	(0)	(0)	(0)	(0)	(0)	(0)
Anus, Epithelium, Hyperplasia						
Anus, Inflammation, Chronic Active						
Anus, Ulcer						
Intestine Large, Cecum	(39)	(37)	(40)	(31)	(46)	(40)
Hemorrhage						
Lymphoid Tiss, Hyperplasia						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:12:59

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Intestine Large, Colon	(44)	(42)	(41)	(37)	(47)	(43)
Lymphoid Tiss, Hyperplasia						1 (2%)
Intestine Large, Rectum	(45)	(47)	(45)	(44)	(47)	(47)
Anus, Cyst						
Anus, Erosion, Focal						
Anus, Inflammation, Acute						
Cyst	1 (2%)					
Epithelium, Hyperplasia						
Erosion		1 (2%)				
Inflammation, Acute						
Inflammation, Chronic						
Inflammation, Chronic Active		3 (6%)			1 (2%)	
Necrosis	1 (2%)					
Serosa, Infiltration Cellular, Lymphocytic	1 (2%)					
Serosa, Inflammation, Acute					1 (2%)	
Serosa, Inflammation, Chronic Active						
Ulcer					1 (2%)	
Intestine Small, Duodenum	(35)	(38)	(36)	(26)	(43)	(42)
Inflammation, Chronic Active				1 (4%)		
Lymphoid Tiss, Hyperplasia						
Intestine Small, Ileum	(37)	(37)	(35)	(26)	(42)	(42)
Inflammation, Chronic						
Inflammation, Chronic Active				1 (4%)	1 (2%)	
Lymphoid Tiss, Hyperplasia						1 (2%)
Intestine Small, Jejunum	(39)	(39)	(37)	(24)	(42)	(41)
Inflammation, Chronic Active				1 (4%)		
Liver	(46)	(47)	(46)	(44)	(47)	(48)
Amyloid Deposition		1 (2%)				
Angiectasis		4 (9%)	6 (13%)	17 (39%)		
Basophilic Focus	1 (2%)	1 (2%)	2 (4%)	1 (2%)	2 (4%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:00

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Basophilic Focus	1 (2%)	1 (2%)	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Bile Duct, Cyst	1 (2%)		2 (4%)		1 (2%)	
Bile Duct, Hyperplasia			1 (2%)			
Clear Cell Focus	3 (7%)		5 (11%)	2 (5%)		3 (6%)
Eosinophilic Focus	6 (13%)	6 (13%)	19 (41%)	28 (64%)	6 (13%)	3 (6%)
Eosinophilic Focus, Multiple		1 (2%)				
Hematopoietic Cell Proliferation	1 (2%)	5 (11%)	9 (20%)	11 (25%)	6 (13%)	1 (2%)
Hepatocyte, Hypertrophy	1 (2%)					
Hepatocyte, Necrosis	3 (7%)	5 (11%)	5 (11%)	3 (7%)	4 (9%)	6 (13%)
Hepatocyte, Nuclear Alteration	3 (7%)				1 (2%)	2 (4%)
Hepatocyte, Syncytial Alteration	8 (17%)	6 (13%)	8 (17%)	1 (2%)	9 (19%)	6 (13%)
Hepatocyte, Vacuolization Cytoplasmic	2 (4%)	3 (6%)	1 (2%)		5 (11%)	4 (8%)
Infiltration Cellular, Lymphocytic	1 (2%)	2 (4%)				2 (4%)
Infiltration Cellular, Mixed Cell	1 (2%)	3 (6%)	4 (9%)	2 (5%)	5 (11%)	3 (6%)
Inflammation, Chronic Active						
Inflammation, Subacute		1 (2%)				
Kupffer Cell, Hyperplasia	5 (11%)	10 (21%)	10 (22%)	12 (27%)	7 (15%)	12 (25%)
Median Lobe, Infarct						
Mixed Cell Focus	1 (2%)	1 (2%)	3 (7%)			3 (6%)
Necrosis	3 (7%)	2 (4%)	2 (4%)	5 (11%)	3 (6%)	4 (8%)
Oval Cell, Hyperplasia		1 (2%)				1 (2%)
Pigmentation					1 (2%)	
Regeneration		1 (2%)	2 (4%)	1 (2%)		1 (2%)
Tension Lipidosis	1 (2%)					
Mesentery	(1)	(1)	(1)	(1)	(0)	(3)
Cyst			1 (100%)			
Fat, Necrosis	1 (100%)	1 (100%)				1 (33%)
Inflammation, Chronic						
Pancreas	(45)	(44)	(44)	(42)	(47)	(45)
Acinar Cell, Atrophy	1 (2%)			1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:00

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Acinar Cell, Degeneration						
Acinar Cell, Hyperplasia, Focal						1 (2%)
Acinar Cell, Vacuolization Cytoplasmic		1 (2%)			3 (6%)	1 (2%)
Amyloid Deposition						1 (2%)
Basophilic Focus				1 (2%)		
Duct, Dilatation						
Eosinophilic Focus						1 (2%)
Infiltration Cellular, Lymphocytic	4 (9%)	3 (7%)	5 (11%)	2 (5%)	2 (4%)	5 (11%)
Inflammation, Chronic						
Inflammation, Chronic Active						
Necrosis				1 (2%)		
Salivary Glands	(47)	(48)	(46)	(46)	(48)	(48)
Atrophy	2 (4%)	4 (8%)	2 (4%)	4 (9%)	2 (4%)	1 (2%)
Duct, Hyperplasia						
Hyperplasia	1 (2%)					
Infiltration Cellular, Lymphocytic	32 (68%)	37 (77%)	39 (85%)	26 (57%)	33 (69%)	37 (77%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Chronic						
Inflammation, Chronic Active						
Mineralization						
Parotid Gl, Atrophy						1 (2%)
Stomach, Forestomach	(46)	(47)	(44)	(45)	(47)	(47)
Cyst			1 (2%)			2 (4%)
Diverticulum				1 (2%)		
Epithelium, Cytoplasmic Alteration				1 (2%)		
Epithelium, Hyperplasia	1 (2%)		4 (9%)	1 (2%)	1 (2%)	3 (6%)
Erosion						1 (2%)
Inflammation						
Inflammation, Chronic Active						
Stomach, Glandular	(43)	(43)	(44)	(42)	(47)	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:00

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Stomach, Glandular	(43)	(43)	(44)	(42)	(47)	(45)
Cyst	1 (2%)	3 (7%)	3 (7%)	1 (2%)	1 (2%)	2 (4%)
Ectopic Tissue		1 (2%)				
Epithelium, Hyperplasia		1 (2%)				1 (2%)
Erosion	1 (2%)		1 (2%)	1 (2%)		
Infiltration Cellular, Lymphocytic	1 (2%)	1 (2%)			1 (2%)	2 (4%)
Inflammation, Acute	2 (5%)				1 (2%)	
Inflammation, Chronic		1 (2%)			1 (2%)	
Inflammation, Subacute	1 (2%)			1 (2%)		
Metaplasia, Squamous						
Mineralization		1 (2%)				
Mucosa, Angiectasis						
Serosa, Angiectasis						
Ulcer						
Tongue	(47)	(48)	(47)	(48)	(47)	(48)
Artery, Inflammation, Chronic						
Epithelium, Hyperplasia, Focal						
Foreign Body						
Infiltration Cellular, Lymphocytic	1 (2%)					1 (2%)
Inflammation, Chronic						1 (2%)
Inflammation, Chronic Active						
Necrosis	1 (2%)					
CARDIOVASCULAR SYSTEM						
Blood Vessel	(47)	(46)	(47)	(45)	(48)	(48)
Mineralization						
Heart	(48)	(48)	(47)	(48)	(48)	(48)
Abscess						
Angiectasis		1 (2%)	2 (4%)	11 (23%)		
Artery, Inflammation, Chronic					2 (4%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:00

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Atrium, Infiltration Cellular, Lymphocytic	1 (2%)					
Atrium, Thrombosis				1 (2%)		
Bacterium			1 (2%)			
Cardiomyopathy		1 (2%)				
Endothelium, Hyperplasia			4 (9%)	9 (19%)		1 (2%)
Epicardium, Inflammation, Acute						1 (2%)
Epicardium, Inflammation, Chronic			1 (2%)			
Epicardium, Inflammation, Subacute						
Inflammation, Chronic						
Mineralization		2 (4%)	2 (4%)			1 (2%)
Myocardium, Inflammation, Acute	2 (4%)		1 (2%)			
Myocardium, Inflammation, Chronic		2 (4%)	2 (4%)	1 (2%)		
Necrosis		1 (2%)	1 (2%)		1 (2%)	
Parenchym Cell, Hypertrophy		2 (4%)		1 (2%)	4 (8%)	
Valve, Bacterium						
Valve, Inflammation, Acute			1 (2%)	1 (2%)		
Valve, Inflammation, Chronic			2 (4%)		1 (2%)	
Valve, Inflammation, Chronic Active						
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(0)	(0)	(0)	(0)	(0)
Adrenal Gland, Cortex	(44)	(44)	(44)	(44)	(46)	(45)
Angiectasis			1 (2%)			
Cyst	1 (2%)					
Degeneration			1 (2%)			
Hyperplasia, Focal	1 (2%)	1 (2%)	4 (9%)	2 (5%)	1 (2%)	2 (4%)
Hypertrophy	8 (18%)	7 (16%)	3 (7%)	2 (5%)	6 (13%)	5 (11%)
Necrosis						
Subcapsular, Hyperplasia	38 (86%)	35 (80%)	33 (75%)	36 (82%)	35 (76%)	38 (84%)
Subcapsular, Hyperplasia, Focal						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:00

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Vacuolization Cytoplasmic, Focal						
Adrenal Gland, Medulla	(44)	(43)	(42)	(43)	(44)	(42)
Amyloid Deposition			1 (2%)			
Fibrosis				1 (2%)		
Hyperplasia			3 (7%)	1 (2%)	3 (7%)	1 (2%)
Pigmentation			1 (2%)			
Islets, Pancreatic	(45)	(44)	(44)	(42)	(47)	(45)
Hyperplasia	4 (9%)	2 (5%)	2 (5%)	2 (5%)	2 (4%)	3 (7%)
Infiltration Cellular, Lymphocytic						
Parathyroid Gland	(42)	(33)	(30)	(28)	(37)	(40)
Cyst	1 (2%)	1 (3%)			2 (5%)	1 (3%)
Infiltration Cellular, Lymphocytic		1 (3%)		1 (4%)		
Inflammation, Acute	1 (2%)					
Pituitary Gland	(35)	(42)	(39)	(38)	(46)	(42)
Pars Distalis, Cyst		1 (2%)		1 (3%)	2 (4%)	1 (2%)
Pars Distalis, Hyperplasia, Focal				1 (3%)		
Thyroid Gland	(46)	(46)	(46)	(45)	(46)	(48)
C Cell, Hyperplasia, Focal						
Crystals	1 (2%)	1 (2%)			1 (2%)	
Follicle, Cyst		1 (2%)		3 (7%)		1 (2%)
Follicular Cel, Hyperplasia						
Follicular Cel, Hyperplasia, Focal				1 (2%)		
Infiltration Cellular, Lymphocytic		1 (2%)			1 (2%)	1 (2%)
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic	1 (2%)				1 (2%)	1 (2%)
Ultimobranchial Cyst	8 (17%)	10 (22%)	12 (26%)	9 (20%)	11 (24%)	7 (15%)
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(1)	(0)

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:01

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Coagulating Gland	(46)	(48)	(46)	(46)	(46)	(48)
Atrophy	1 (2%)	2 (4%)	5 (11%)	5 (11%)	4 (9%)	6 (13%)
Cyst						
Dilatation	1 (2%)	3 (6%)	1 (2%)		1 (2%)	
Infiltration Cellular, Lymphocytic	9 (20%)	5 (10%)	3 (7%)		4 (9%)	6 (13%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Acute	2 (4%)				1 (2%)	
Inflammation, Chronic						
Inflammation, Chronic Active						1 (2%)
Inflammation, Subacute						1 (2%)
Epididymis	(47)	(48)	(46)	(44)	(48)	(48)
Atrophy						
Epithelium, Hyperplasia, Focal						
Fibrosis						
Granuloma Sperm						1 (2%)
Infiltration Cellular, Lymphocytic	5 (11%)	4 (8%)	12 (26%)	4 (9%)	9 (19%)	7 (15%)
Infiltration Cellular, Mixed Cell		1 (2%)			1 (2%)	
Inflammation, Chronic	3 (6%)	3 (6%)		1 (2%)		1 (2%)
Inflammation, Chronic Active						
Inflammation, Subacute	1 (2%)			1 (2%)		
Mineralization	1 (2%)			1 (2%)		
Necrosis	1 (2%)					
Penis	(0)	(1)	(1)	(2)	(0)	(0)
Adventitia, Inflammation, Chronic						
Cyst			1 (100%)			
Hyperplasia				1 (50%)		
Inflammation, Acute						
Inflammation, Chronic			1 (100%)			
Inflammation, Chronic Active		1 (100%)		1 (50%)		
Preputial Gland	(45)	(44)	(43)	(43)	(46)	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:01

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Preputial Gland	(45)	(44)	(43)	(43)	(46)	(45)
Angiectasis	1 (2%)	1 (2%)				
Atrophy	18 (40%)	14 (32%)	14 (33%)	28 (65%)	14 (30%)	19 (42%)
Cyst		1 (2%)			1 (2%)	2 (4%)
Degeneration						
Dilatation	7 (16%)	20 (45%)	16 (37%)	10 (23%)	15 (33%)	14 (31%)
Hyperplasia						
Inflammation, Acute	3 (7%)	3 (7%)			1 (2%)	
Inflammation, Chronic	7 (16%)	6 (14%)	9 (21%)	9 (21%)	11 (24%)	8 (18%)
Inflammation, Chronic Active	10 (22%)	12 (27%)	9 (21%)	10 (23%)	9 (20%)	3 (7%)
Inflammation, Subacute			1 (2%)	1 (2%)		1 (2%)
Prostate	(46)	(45)	(45)	(45)	(46)	(47)
Artery, Inflammation, Chronic	1 (2%)					
Atrophy	1 (2%)	1 (2%)	1 (2%)	5 (11%)		2 (4%)
Dilatation		1 (2%)				
Epithelium, Hyperplasia			1 (2%)			1 (2%)
Infiltration Cellular, Lymphocytic	2 (4%)	2 (4%)	1 (2%)	1 (2%)		1 (2%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Acute	3 (7%)	2 (4%)	1 (2%)	3 (7%)	2 (4%)	
Inflammation, Chronic						
Inflammation, Chronic Active						
Inflammation, Subacute	15 (33%)	16 (36%)	13 (29%)	5 (11%)	14 (30%)	10 (21%)
Seminal Vesicle	(46)	(48)	(46)	(46)	(47)	(48)
Atrophy	2 (4%)	3 (6%)	4 (9%)	5 (11%)	6 (13%)	7 (15%)
Dilatation	5 (11%)	2 (4%)	4 (9%)			
Infiltration Cellular, Lymphocytic			1 (2%)	1 (2%)		1 (2%)
Inflammation, Acute	1 (2%)	2 (4%)		1 (2%)	1 (2%)	
Inflammation, Chronic			1 (2%)			2 (4%)
Inflammation, Chronic Active						1 (2%)
Testes	(47)	(48)	(46)	(46)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:01

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Cyst						
Developmental Malformation			1 (2%)			
Fibrosis						
Germinal Epith, Atrophy	2 (4%)	4 (8%)	3 (7%)	2 (4%)	2 (4%)	3 (6%)
Germinal Epith, Degeneration	3 (6%)	4 (8%)	3 (7%)	1 (2%)	2 (4%)	3 (6%)
Hemorrhage				1 (2%)		1 (2%)
Mineralization	1 (2%)	1 (2%)		2 (4%)	3 (6%)	2 (4%)
Ovotestis			1 (2%)			
HEMATOPOIETIC SYSTEM						
Bone Marrow	(46)	(47)	(45)	(45)	(48)	(48)
Angiectasis			2 (4%)			2 (4%)
Depletion						
Fibrosis						
Hemorrhage						
Hyperplasia	6 (13%)	6 (13%)	6 (13%)	10 (22%)	12 (25%)	4 (8%)
Myelofibrosis						
Necrosis	1 (2%)					1 (2%)
Thrombosis			1 (2%)			
Lymph Node	(2)	(7)	(7)	(6)	(5)	(3)
Axillary, Hemorrhage						
Axillary, Hyperplasia				1 (17%)	1 (20%)	
Inguinal, Degeneration, Cystic		1 (14%)				
Inguinal, Hemorrhage				1 (17%)		
Inguinal, Hyperplasia		1 (14%)		2 (33%)	1 (20%)	
Inguinal, Infiltration Cellular, Histiocytic						
Inguinal, Pigmentation						
Lumbar, Hyperplasia	1 (50%)					
Lumbar, Infiltration Cellular, Mixed Cell					1 (20%)	
Renal, Autolysis			1 (14%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:01

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Renal, Hyperplasia			2 (29%)	2 (33%)		
Thoracic, Hyperplasia						
Lymph Node, Mandibular	(46)	(46)	(46)	(45)	(48)	(48)
Angiectasis			1 (2%)			
Atrophy						
Congestion						
Cyst						
Depletion Lymphoid						1 (2%)
Hemorrhage		1 (2%)		1 (2%)		
Hyperplasia	12 (26%)	9 (20%)	17 (37%)	11 (24%)	13 (27%)	9 (19%)
Infiltration Cellular, Histiocytic	4 (9%)	3 (7%)	2 (4%)	4 (9%)	2 (4%)	4 (8%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Chronic						
Mineralization	1 (2%)					
Pigmentation	1 (2%)		1 (2%)		2 (4%)	
Lymph Node, Mesenteric	(43)	(47)	(43)	(38)	(48)	(48)
Angiectasis	22 (51%)	21 (45%)	25 (58%)	17 (45%)	18 (38%)	20 (42%)
Depletion Lymphoid						
Hematopoietic Cell Proliferation				1 (3%)		
Hemorrhage		1 (2%)		2 (5%)	1 (2%)	
Hyperplasia	6 (14%)	13 (28%)	11 (26%)	5 (13%)	13 (27%)	12 (25%)
Hyperplasia, Lymphoid						
Infiltration Cellular, Histiocytic	2 (5%)			2 (5%)		2 (4%)
Infiltration Cellular, Lymphocytic		1 (2%)				
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Acute					1 (2%)	
Inflammation, Chronic Active						
Necrosis		1 (2%)				
Vein, Thrombosis						
Spleen	(44)	(46)	(45)	(42)	(46)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:02

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Angiectasis			2 (4%)		1 (2%)	1 (2%)
Congestion					1 (2%)	
Hematopoietic Cell Proliferation	19 (43%)	22 (48%)	17 (38%)	32 (76%)	20 (43%)	16 (35%)
Infiltration Cellular, Histiocytic						1 (2%)
Infiltration Cellular, Lymphocytic		1 (2%)				
Inflammation, Chronic Active				1 (2%)		
Lymph Follic, Atrophy	3 (7%)	3 (7%)		1 (2%)		1 (2%)
Lymph Follic, Hyperplasia	10 (23%)	16 (35%)	20 (44%)	2 (5%)	19 (41%)	21 (46%)
Metaplasia, Osseous						
Necrosis				1 (2%)		
Pigmentation			1 (2%)			1 (2%)
Thymus	(32)	(29)	(35)	(27)	(35)	(32)
Atrophy	15 (47%)	11 (38%)	14 (40%)	18 (67%)	12 (34%)	13 (41%)
Cortex, Hyperplasia			1 (3%)			
Cyst	3 (9%)		2 (6%)	1 (4%)	8 (23%)	4 (13%)
Epithel Cell, Hyperplasia			1 (3%)			
Hemorrhage						
Infiltration Cellular, Mixed Cell					1 (3%)	
Medulla, Hyperplasia	1 (3%)	1 (3%)				
Necrosis						1 (3%)
INTEGUMENTARY SYSTEM						
Mammary Gland	(0)	(2)	(5)	(1)	(0)	(2)
Cyst			1 (20%)			
Skin	(47)	(48)	(47)	(48)	(48)	(48)
Edema			2 (4%)	1 (2%)	1 (2%)	1 (2%)
Epithelium, Hyperplasia	2 (4%)	2 (4%)				4 (8%)
Erosion	1 (2%)			1 (2%)	1 (2%)	1 (2%)
Fat, Necrosis						
Inflammation, Acute	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:02

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Inflammation, Chronic	4 (9%)	4 (8%)		3 (6%)	1 (2%)	5 (10%)
Inflammation, Chronic Active	1 (2%)	3 (6%)		1 (2%)	2 (4%)	
Metaplasia, Osseous	1 (2%)	2 (4%)			1 (2%)	
Prepuce, Inflammation, Acute						1 (2%)
Prepuce, Inflammation, Chronic Active						
Sebaceous GI, Hyperplasia				1 (2%)		
Ulcer	3 (6%)	3 (6%)			1 (2%)	
MUSCULOSKELETAL SYSTEM						
Bone	(48)	(48)	(47)	(48)	(48)	(48)
Calvarium, Hyperostosis						
Cartilage, Femur, Joint, Degeneration	3 (6%)	12 (25%)	10 (21%)	3 (6%)	9 (19%)	9 (19%)
Cartilage, Sternum, Degeneration						
Cranium, Hyperostosis						
Femur, Hyperostosis				1 (2%)		
Femur, Joint, Hyperostosis				1 (2%)		
Femur, Joint, Inflammation, Acute						
Femur, Joint, Inflammation, Chronic						
Femur, Joint, Inflammation, Chronic Active						1 (2%)
Femur, Osteomalacia	1 (2%)					
Periosteum, Sternum, Inflammation, Chronic						
Sternum, Hyperostosis	2 (4%)			1 (2%)		
Sternum, Inflammation, Acute						
Sternum, Osteomalacia				1 (2%)		
Skeletal Muscle	(48)	(48)	(47)	(48)	(48)	(48)
Infiltration Cellular, Lymphocytic	2 (4%)	3 (6%)	4 (9%)	2 (4%)	2 (4%)	2 (4%)
Inflammation, Subacute			1 (2%)			
Mineralization			1 (2%)			1 (2%)
Necrosis	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:02

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Regeneration						
NERVOUS SYSTEM						
Brain, Cerebellum	(48)	(47)	(44)	(46)	(47)	(48)
Hemorrhage						
Meninges, Inflammation, Acute			1 (2%)			
Meninges, Mineralization						
Necrosis						
Brain, Cerebrum	(48)	(48)	(47)	(47)	(48)	(48)
Cyst Epithelial Inclusion		1 (2%)				
Inflammation, Acute			1 (2%)			
Meninges, Inflammation, Acute						
Necrosis				1 (2%)		
Thalamus, Mineralization	25 (52%)	24 (50%)	23 (49%)	17 (36%)	27 (56%)	25 (52%)
Peripheral Nerve	(47)	(48)	(47)	(48)	(48)	(48)
Degeneration	6 (13%)	7 (15%)	5 (11%)	2 (4%)	3 (6%)	5 (10%)
Spinal Cord, Thoracic	(47)	(48)	(47)	(48)	(48)	(48)
Meninges, Inflammation, Acute						
Necrosis						1 (2%)
RESPIRATORY SYSTEM						
Larynx	(45)	(45)	(46)	(45)	(44)	(47)
Atrophy						
Cyst						2 (4%)
Infiltration Cellular, Lymphocytic						
Inflammation, Acute				1 (2%)		
Inflammation, Chronic		1 (2%)				
Inflammation, Subacute						1 (2%)
Lung	(48)	(48)	(47)	(48)	(48)	(48)
Alveolar Epith, Hyperplasia	2 (4%)	1 (2%)	6 (13%)	11 (23%)		3 (6%)
Bronchiole, Epithelium, Hyperplasia						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:02

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Foreign Body					1 (2%)	1 (2%)
Hemorrhage				1 (2%)		
Infiltration Cellular, Histiocytic			1 (2%)	3 (6%)		2 (4%)
Infiltration Cellular, Lymphocytic	6 (13%)	7 (15%)	6 (13%)		6 (13%)	4 (8%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Chronic	2 (4%)	1 (2%)		1 (2%)	2 (4%)	1 (2%)
Inflammation, Chronic Active	1 (2%)	1 (2%)			1 (2%)	1 (2%)
Parasite Protozoan		1 (2%)				
Pigmentation			1 (2%)	1 (2%)		1 (2%)
Pleura, Infiltration Cellular, Lymphocytic	1 (2%)					
Vein, Inflammation, Acute						
Vein, Inflammation, Chronic						
Vein, Inflammation, Subacute			1 (2%)			
Nose	(47)	(48)	(47)	(47)	(48)	(48)
Foreign Body						1 (2%)
Glands, Hyperplasia					1 (2%)	
Inflammation			2 (4%)	1 (2%)		
Mucosa, Cyst	1 (2%)				1 (2%)	
Nasolacrim Dct, Inflammation, Acute						
Nasolacrim Dct, Inflammation, Chronic						
Olfactory Epi, Cytoplasmic Alteration	20 (43%)	27 (56%)	21 (45%)	16 (34%)	13 (27%)	12 (25%)
Respirat Epith, Cytoplasmic Alteration	26 (55%)	25 (52%)	22 (47%)	17 (36%)	15 (31%)	9 (19%)
Trachea	(47)	(47)	(46)	(46)	(47)	(48)
Inflammation, Acute					1 (2%)	
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Inflammation, Chronic Active						
Ulcer						
Eye	(47)	(47)	(47)	(47)	(47)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:03

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Atrophy				1 (2%)		
Cornea, Degeneration				1 (2%)		
Cornea, Hyperplasia			1 (2%)			
Cornea, Inflammation, Acute	1 (2%)			1 (2%)		
Cornea, Inflammation, Chronic			6 (13%)	6 (13%)		
Cornea, Inflammation, Chronic Active		1 (2%)		2 (4%)		
Inflammation, Chronic Active						1 (2%)
Iris, Inflammation, Acute				1 (2%)		
Lens, Cataract		1 (2%)	3 (6%)			1 (2%)
Lids, Inflammation, Chronic Active			1 (2%)			
Mineralization						
Optic Nerve, Inflammation, Acute						
Harderian Gland	(47)	(47)	(47)	(47)	(48)	(48)
Hyperplasia, Focal		1 (2%)	4 (9%)	2 (4%)		
Infiltration Cellular, Lymphocytic	18 (38%)	18 (38%)	11 (23%)	5 (11%)	16 (33%)	18 (38%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Chronic		1 (2%)		1 (2%)		
Inflammation, Chronic Active						
Lacrimal Gland	(47)	(47)	(44)	(47)	(48)	(47)
Amyloid Deposition						
Atrophy	7 (15%)	10 (21%)	5 (11%)	8 (17%)	7 (15%)	8 (17%)
Atrophy, Focal				1 (2%)		
Cyst						
Degeneration						
Duct, Hyperplasia						1 (2%)
Hyperplasia, Focal			1 (2%)			
Infiltration Cellular, Lymphocytic	20 (43%)	15 (32%)	11 (25%)	11 (23%)	9 (19%)	12 (26%)
Infiltration Cellular, Mast Cell						
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Chronic Active						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:03

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Inflammation, Chronic Active						
Mineralization					1 (2%)	
Necrosis						
Zymbal's Gland	(45)	(45)	(45)	(45)	(47)	(45)
Cyst					1 (2%)	1 (2%)
Dilatation			1 (2%)	1 (2%)		
Hyperplasia			2 (4%)		1 (2%)	
Infiltration Cellular, Lymphocytic						
Inflammation, Subacute						
URINARY SYSTEM						
Kidney	(46)	(47)	(46)	(45)	(48)	(48)
Amyloid Deposition		5 (11%)			4 (8%)	4 (8%)
Artery, Inflammation, Chronic						
Atrophy					1 (2%)	
Atrophy, Focal						
Bacterium					1 (2%)	
Cyst	4 (9%)	2 (4%)	5 (11%)	3 (7%)	6 (13%)	5 (10%)
Glomerulosclerosis	30 (65%)	35 (74%)	35 (76%)	27 (60%)	35 (73%)	32 (67%)
Glomerulus, Thrombosis				1 (2%)		
Hematopoietic Cell Proliferation			1 (2%)			
Hypoplasia, Focal			1 (2%)			
Infarct						
Infiltration Cellular, Lymphocytic	15 (33%)	17 (36%)	21 (46%)	18 (40%)	29 (60%)	28 (58%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Acute					1 (2%)	
Inflammation, Chronic	1 (2%)			1 (2%)		
Inflammation, Chronic Active					1 (2%)	
Metaplasia, Osseous					1 (2%)	
Mineralization	8 (17%)	8 (17%)	7 (15%)	3 (7%)	7 (15%)	7 (15%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:03

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Nephropathy		1 (2%)				
Papilla, Necrosis		1 (2%)				1 (2%)
Pelvis, Dilatation		1 (2%)			2 (4%)	1 (2%)
Pelvis, Inflammation					1 (2%)	
Pelvis, Inflammation, Acute	4 (9%)	1 (2%)			1 (2%)	1 (2%)
Pelvis, Inflammation, Chronic		1 (2%)	2 (4%)			
Pelvis, Inflammation, Chronic Active						1 (2%)
Pelvis, Inflammation, Subacute		1 (2%)				
Pelvis, Mineralization						1 (2%)
Pigmentation	1 (2%)			1 (2%)		
Renal Tubule, Accumulation, Hyaline Droplet			1 (2%)			1 (2%)
Renal Tubule, Degeneration	18 (39%)	21 (45%)	10 (22%)	7 (16%)	20 (42%)	14 (29%)
Renal Tubule, Hyperplasia, Focal	1 (2%)	2 (4%)		1 (2%)	3 (6%)	1 (2%)
Renal Tubule, Necrosis						
Vein, Thrombosis				1 (2%)		
Ureter	(0)	(0)	(0)	(0)	(0)	(0)
Urethra	(0)	(1)	(0)	(1)	(0)	(0)
Bulboureth GI, Congestion		1 (100%)				
Bulboureth GI, Inflammation, Acute						
Urinary Bladder	(46)	(46)	(46)	(40)	(47)	(46)
Calculus Gross Observation						
Dilatation	1 (2%)	1 (2%)		2 (5%)		1 (2%)
Edema	1 (2%)	1 (2%)	1 (2%)	1 (3%)		
Infiltration Cellular, Lymphocytic	19 (41%)	21 (46%)	20 (43%)	9 (23%)	24 (51%)	23 (50%)
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Acute	4 (9%)	2 (4%)	1 (2%)	4 (10%)	2 (4%)	
Inflammation, Chronic						
Inflammation, Chronic Active	2 (4%)					
Mineralization	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:13:03
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse MALE

**0% ETH/ 0PPM URE 0% ETH/ 10PPMURE 0% ETH/ 30PPMURE 0% ETH/ 90PPMURE 2.5%ETH/0PPM URE 2.5%ETH/10PPMUR
E**

Transit Epithe, Hyperplasia
Ulcer

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:03

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Moribund	5	6	4	3	6	11
Natural Death	14	19	4	12	15	17
Survivors						
Moribund	2	3	1	3		4
Natural Death	2	4	3	1	2	4
Terminal Sacrifice	25	16	36	29	25	12
Animals Examined Microscopically	47	48	48	48	48	48
ALIMENTARY SYSTEM						
Esophagus	(46)	(48)	(47)	(46)	(48)	(48)
Gallbladder	(40)	(39)	(42)	(37)	(30)	(32)
Concretion						
Cyst						
Epithelium, Cytoplasmic Alteration					1 (3%)	
Infiltration Cellular, Lymphocytic						
Inflammation, Acute				2 (5%)		
Inflammation, Chronic			2 (5%)			1 (3%)
Inflammation, Subacute				1 (3%)		
Mucosa, Cyst					1 (3%)	
Pigmentation	1 (3%)					
Intestine Large	(0)	(0)	(0)	(0)	(2)	(2)
Anus, Epithelium, Hyperplasia						1 (50%)
Anus, Inflammation, Chronic Active					1 (50%)	
Anus, Ulcer					1 (50%)	
Intestine Large, Cecum	(42)	(43)	(45)	(45)	(38)	(39)
Hemorrhage		1 (2%)				
Lymphoid Tiss, Hyperplasia				1 (2%)	1 (3%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:03

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Intestine Large, Colon	(44)	(46)	(47)	(45)	(43)	(43)
Lymphoid Tiss, Hyperplasia						
Intestine Large, Rectum	(47)	(47)	(47)	(46)	(48)	(46)
Anus, Cyst				1 (2%)		
Anus, Erosion, Focal	1 (2%)					
Anus, Inflammation, Acute				1 (2%)		
Cyst						
Epithelium, Hyperplasia						1 (2%)
Erosion					1 (2%)	
Inflammation, Acute						1 (2%)
Inflammation, Chronic					1 (2%)	
Inflammation, Chronic Active						1 (2%)
Necrosis						
Serosa, Infiltration Cellular, Lymphocytic						
Serosa, Inflammation, Acute						
Serosa, Inflammation, Chronic Active	1 (2%)					
Ulcer						
Intestine Small, Duodenum	(40)	(42)	(46)	(43)	(36)	(38)
Inflammation, Chronic Active						
Lymphoid Tiss, Hyperplasia			1 (2%)			
Intestine Small, Ileum	(41)	(41)	(42)	(43)	(36)	(39)
Inflammation, Chronic			1 (2%)			
Inflammation, Chronic Active						
Lymphoid Tiss, Hyperplasia						
Intestine Small, Jejunum	(41)	(37)	(45)	(46)	(38)	(36)
Inflammation, Chronic Active						
Liver	(46)	(48)	(48)	(46)	(48)	(48)
Amyloid Deposition	1 (2%)			1 (2%)	1 (2%)	
Angiectasis	7 (15%)	16 (33%)	1 (2%)	1 (2%)	8 (17%)	19 (40%)
Basophilic Focus	1 (2%)	2 (4%)	1 (2%)	4 (9%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:04

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Basophilic Focus	1 (2%)	2 (4%)	1 (2%)	4 (9%)	1 (2%)	
Bile Duct, Cyst			1 (2%)			1 (2%)
Bile Duct, Hyperplasia						2 (4%)
Clear Cell Focus	5 (11%)		2 (4%)	4 (9%)	4 (8%)	
Eosinophilic Focus	17 (37%)	22 (46%)	10 (21%)	9 (20%)	18 (38%)	25 (52%)
Eosinophilic Focus, Multiple						
Hematopoietic Cell Proliferation	5 (11%)	11 (23%)	1 (2%)	1 (2%)	5 (10%)	13 (27%)
Hepatocyte, Hypertrophy						
Hepatocyte, Necrosis	5 (11%)	3 (6%)	7 (15%)	5 (11%)	2 (4%)	5 (10%)
Hepatocyte, Nuclear Alteration	1 (2%)		1 (2%)	3 (7%)	6 (13%)	3 (6%)
Hepatocyte, Syncytial Alteration	5 (11%)	4 (8%)	16 (33%)	13 (28%)	10 (21%)	5 (10%)
Hepatocyte, Vacuolization Cytoplasmic	2 (4%)	1 (2%)	2 (4%)	5 (11%)	4 (8%)	1 (2%)
Infiltration Cellular, Lymphocytic				2 (4%)		
Infiltration Cellular, Mixed Cell	5 (11%)		4 (8%)	3 (7%)	2 (4%)	
Inflammation, Chronic Active	1 (2%)					1 (2%)
Inflammation, Subacute						
Kupffer Cell, Hyperplasia	9 (20%)	13 (27%)	7 (15%)	9 (20%)	10 (21%)	13 (27%)
Median Lobe, Infarct			1 (2%)			
Mixed Cell Focus	4 (9%)	1 (2%)	1 (2%)	4 (9%)	5 (10%)	
Necrosis	4 (9%)	4 (8%)	3 (6%)	1 (2%)	3 (6%)	4 (8%)
Oval Cell, Hyperplasia			1 (2%)			1 (2%)
Pigmentation						
Regeneration	1 (2%)	9 (19%)			3 (6%)	5 (10%)
Tension Lipidosis			1 (2%)			
Mesentery	(2)	(3)	(4)	(1)	(2)	(0)
Cyst						
Fat, Necrosis	1 (50%)	1 (33%)	3 (75%)	1 (100%)		
Inflammation, Chronic					1 (50%)	
Pancreas	(46)	(46)	(48)	(46)	(45)	(44)
Acinar Cell, Atrophy			1 (2%)			1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:04

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Acinar Cell, Degeneration	1 (2%)			1 (2%)		
Acinar Cell, Hyperplasia, Focal						
Acinar Cell, Vacuolization Cytoplasmic		1 (2%)			1 (2%)	2 (5%)
Amyloid Deposition						
Basophilic Focus	1 (2%)					
Duct, Dilatation					1 (2%)	
Eosinophilic Focus						
Infiltration Cellular, Lymphocytic	2 (4%)	1 (2%)	1 (2%)	7 (15%)	4 (9%)	1 (2%)
Inflammation, Chronic	1 (2%)					
Inflammation, Chronic Active						1 (2%)
Necrosis						1 (2%)
Salivary Glands	(46)	(48)	(48)	(48)	(48)	(48)
Atrophy	2 (4%)	3 (6%)	8 (17%)	2 (4%)	3 (6%)	8 (17%)
Duct, Hyperplasia			1 (2%)			
Hyperplasia						
Infiltration Cellular, Lymphocytic	28 (61%)	29 (60%)	40 (83%)	38 (79%)	34 (71%)	16 (33%)
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic			1 (2%)			
Inflammation, Chronic Active	1 (2%)					
Mineralization	1 (2%)				1 (2%)	
Parotid Gl, Atrophy						
Stomach, Forestomach	(46)	(46)	(48)	(47)	(45)	(48)
Cyst	1 (2%)		2 (4%)		1 (2%)	
Diverticulum						
Epithelium, Cytoplasmic Alteration						
Epithelium, Hyperplasia		5 (11%)	1 (2%)		3 (7%)	2 (4%)
Erosion						
Inflammation	1 (2%)					
Inflammation, Chronic Active					1 (2%)	
Stomach, Glandular	(45)	(46)	(48)	(46)	(45)	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:04

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Stomach, Glandular	(45)	(46)	(48)	(46)	(45)	(45)
Cyst				1 (2%)	1 (2%)	
Ectopic Tissue						
Epithelium, Hyperplasia	3 (7%)		1 (2%)			1 (2%)
Erosion	1 (2%)	1 (2%)	1 (2%)	1 (2%)		1 (2%)
Infiltration Cellular, Lymphocytic			1 (2%)		1 (2%)	
Inflammation, Acute						
Inflammation, Chronic			1 (2%)			
Inflammation, Subacute			1 (2%)			
Metaplasia, Squamous			1 (2%)			
Mineralization				1 (2%)		
Mucosa, Angiectasis		1 (2%)				
Serosa, Angiectasis		1 (2%)				
Ulcer				1 (2%)		
Tongue	(46)	(48)	(48)	(48)	(48)	(48)
Artery, Inflammation, Chronic				1 (2%)		
Epithelium, Hyperplasia, Focal	1 (2%)					
Foreign Body	1 (2%)		1 (2%)			2 (4%)
Infiltration Cellular, Lymphocytic						
Inflammation, Chronic	2 (4%)		1 (2%)			2 (4%)
Inflammation, Chronic Active		1 (2%)				
Necrosis						
CARDIOVASCULAR SYSTEM						
Blood Vessel	(45)	(48)	(47)	(46)	(47)	(47)
Mineralization	1 (2%)					
Heart	(47)	(48)	(47)	(48)	(48)	(48)
Abscess				1 (2%)		
Angiectasis	7 (15%)	13 (27%)			1 (2%)	5 (10%)
Artery, Inflammation, Chronic				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:04

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Atrium, Infiltration Cellular, Lymphocytic						
Atrium, Thrombosis					1 (2%)	1 (2%)
Bacterium				3 (6%)		
Cardiomyopathy		2 (4%)	3 (6%)		2 (4%)	
Endothelium, Hyperplasia	4 (9%)	9 (19%)				2 (4%)
Epicardium, Inflammation, Acute						
Epicardium, Inflammation, Chronic	1 (2%)					
Epicardium, Inflammation, Subacute	1 (2%)				1 (2%)	
Inflammation, Chronic				1 (2%)		
Mineralization	1 (2%)		1 (2%)	2 (4%)		1 (2%)
Myocardium, Inflammation, Acute						
Myocardium, Inflammation, Chronic	1 (2%)	3 (6%)		1 (2%)		
Necrosis		1 (2%)				1 (2%)
Parenchym Cell, Hypertrophy	1 (2%)				1 (2%)	3 (6%)
Valve, Bacterium		1 (2%)				
Valve, Inflammation, Acute	1 (2%)			2 (4%)		
Valve, Inflammation, Chronic					1 (2%)	
Valve, Inflammation, Chronic Active		1 (2%)				
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(0)	(0)	(0)	(0)	(1)
Adrenal Gland, Cortex	(46)	(46)	(46)	(47)	(47)	(45)
Angiectasis						
Cyst	1 (2%)			1 (2%)	1 (2%)	
Degeneration						
Hyperplasia, Focal	1 (2%)	1 (2%)	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Hypertrophy	7 (15%)	11 (24%)	9 (20%)	6 (13%)	5 (11%)	5 (11%)
Necrosis				1 (2%)	1 (2%)	
Subcapsular, Hyperplasia	38 (83%)	42 (91%)	39 (85%)	41 (87%)	38 (81%)	39 (87%)
Subcapsular, Hyperplasia, Focal					1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:04

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Vacuolization Cytoplasmic, Focal		1 (2%)				
Adrenal Gland, Medulla	(45)	(46)	(46)	(46)	(46)	(45)
Amyloid Deposition					1 (2%)	
Fibrosis						
Hyperplasia		1 (2%)		1 (2%)		
Pigmentation						
Islets, Pancreatic	(46)	(46)	(48)	(46)	(46)	(44)
Hyperplasia	3 (7%)	2 (4%)	1 (2%)	2 (4%)	2 (4%)	3 (7%)
Infiltration Cellular, Lymphocytic		1 (2%)	1 (2%)			
Parathyroid Gland	(43)	(38)	(38)	(38)	(41)	(37)
Cyst	1 (2%)	1 (3%)			1 (2%)	1 (3%)
Infiltration Cellular, Lymphocytic	1 (2%)					1 (3%)
Inflammation, Acute						
Pituitary Gland	(41)	(42)	(39)	(39)	(42)	(42)
Pars Distalis, Cyst	2 (5%)	1 (2%)		4 (10%)		1 (2%)
Pars Distalis, Hyperplasia, Focal						
Thyroid Gland	(46)	(47)	(45)	(47)	(48)	(47)
C Cell, Hyperplasia, Focal						1 (2%)
Crystals			1 (2%)		1 (2%)	1 (2%)
Follicle, Cyst					1 (2%)	
Follicular Cel, Hyperplasia			1 (2%)		1 (2%)	1 (2%)
Follicular Cel, Hyperplasia, Focal						
Infiltration Cellular, Lymphocytic	1 (2%)		1 (2%)	1 (2%)		
Infiltration Cellular, Mixed Cell					1 (2%)	
Inflammation, Chronic						
Ultimobranchial Cyst	13 (28%)	14 (30%)	10 (22%)	11 (23%)	12 (25%)	10 (21%)
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(0)	(1)

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:05

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Coagulating Gland	(45)	(46)	(47)	(47)	(48)	(44)
Atrophy	4 (9%)	8 (17%)	3 (6%)	5 (11%)	4 (8%)	8 (18%)
Cyst				1 (2%)		
Dilatation				1 (2%)	1 (2%)	1 (2%)
Infiltration Cellular, Lymphocytic	1 (2%)	2 (4%)	3 (6%)	2 (4%)		
Infiltration Cellular, Mixed Cell						
Inflammation, Acute					1 (2%)	
Inflammation, Chronic	1 (2%)					
Inflammation, Chronic Active						1 (2%)
Inflammation, Subacute						
Epididymis	(46)	(48)	(48)	(48)	(48)	(47)
Atrophy				1 (2%)		
Epithelium, Hyperplasia, Focal		1 (2%)				
Fibrosis		1 (2%)				
Granuloma Sperm			1 (2%)			3 (6%)
Infiltration Cellular, Lymphocytic	2 (4%)	3 (6%)	4 (8%)	7 (15%)	2 (4%)	3 (6%)
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic	1 (2%)	2 (4%)		1 (2%)	3 (6%)	3 (6%)
Inflammation, Chronic Active						1 (2%)
Inflammation, Subacute						
Mineralization						
Necrosis						
Penis	(2)	(2)	(0)	(0)	(2)	(0)
Adventitia, Inflammation, Chronic					1 (50%)	
Cyst						
Hyperplasia						
Inflammation, Acute		1 (50%)				
Inflammation, Chronic	1 (50%)	1 (50%)				
Inflammation, Chronic Active	1 (50%)					
Preputial Gland	(45)	(46)	(45)	(46)	(45)	(44)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:05

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Preputial Gland	(45)	(46)	(45)	(46)	(45)	(44)
Angiectasis						
Atrophy	20 (44%)	24 (52%)	13 (29%)	17 (37%)	13 (29%)	29 (66%)
Cyst	2 (4%)			1 (2%)	2 (4%)	2 (5%)
Degeneration	1 (2%)					
Dilatation	15 (33%)	17 (37%)	20 (44%)	17 (37%)	15 (33%)	12 (27%)
Hyperplasia				2 (4%)		
Inflammation, Acute		1 (2%)				
Inflammation, Chronic	6 (13%)	11 (24%)	9 (20%)	7 (15%)	10 (22%)	2 (5%)
Inflammation, Chronic Active	8 (18%)	4 (9%)	10 (22%)	7 (15%)	11 (24%)	11 (25%)
Inflammation, Subacute	1 (2%)	1 (2%)	4 (9%)	1 (2%)		
Prostate	(43)	(48)	(46)	(46)	(45)	(48)
Artery, Inflammation, Chronic						
Atrophy		2 (4%)	1 (2%)	1 (2%)	1 (2%)	5 (10%)
Dilatation						
Epithelium, Hyperplasia	1 (2%)	1 (2%)	1 (2%)			
Infiltration Cellular, Lymphocytic		1 (2%)	1 (2%)			
Infiltration Cellular, Mixed Cell						
Inflammation, Acute	2 (5%)			1 (2%)	1 (2%)	2 (4%)
Inflammation, Chronic					1 (2%)	
Inflammation, Chronic Active	1 (2%)		1 (2%)		1 (2%)	1 (2%)
Inflammation, Subacute	7 (16%)	8 (17%)	19 (41%)	17 (37%)	9 (20%)	7 (15%)
Seminal Vesicle	(46)	(47)	(47)	(47)	(48)	(45)
Atrophy	6 (13%)	10 (21%)	3 (6%)	5 (11%)	3 (6%)	10 (22%)
Dilatation				3 (6%)	2 (4%)	2 (4%)
Infiltration Cellular, Lymphocytic			1 (2%)		1 (2%)	1 (2%)
Inflammation, Acute	1 (2%)				1 (2%)	2 (4%)
Inflammation, Chronic	1 (2%)			1 (2%)	1 (2%)	
Inflammation, Chronic Active						1 (2%)
Testes	(47)	(47)	(48)	(48)	(48)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:05

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Cyst		1 (2%)				
Developmental Malformation						
Fibrosis					1 (2%)	
Germinal Epith, Atrophy	1 (2%)	4 (9%)	2 (4%)	3 (6%)	4 (8%)	2 (4%)
Germinal Epith, Degeneration	1 (2%)	6 (13%)		4 (8%)	2 (4%)	4 (8%)
Hemorrhage						
Mineralization	2 (4%)	4 (9%)	1 (2%)	1 (2%)	3 (6%)	
Ovotestis						
HEMATOPOIETIC SYSTEM						
Bone Marrow	(47)	(46)	(48)	(46)	(46)	(46)
Angiectasis						
Depletion						1 (2%)
Fibrosis			1 (2%)			
Hemorrhage	1 (2%)				1 (2%)	
Hyperplasia	6 (13%)	9 (20%)	5 (10%)	5 (11%)	4 (9%)	5 (11%)
Myelofibrosis					1 (2%)	
Necrosis			1 (2%)			2 (4%)
Thrombosis						
Lymph Node	(4)	(6)	(2)	(3)	(6)	(10)
Axillary, Hemorrhage		1 (17%)				
Axillary, Hyperplasia						
Inguinal, Degeneration, Cystic						
Inguinal, Hemorrhage						
Inguinal, Hyperplasia					1 (17%)	
Inguinal, Infiltration Cellular, Histiocytic				1 (33%)		1 (10%)
Inguinal, Pigmentation						1 (10%)
Lumbar, Hyperplasia	1 (25%)			1 (33%)		
Lumbar, Infiltration Cellular, Mixed Cell						
Renal, Autolysis						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:05

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Renal, Hyperplasia					1 (17%)	
Thoracic, Hyperplasia	1 (25%)					
Lymph Node, Mandibular	(45)	(47)	(48)	(47)	(48)	(47)
Angiectasis		1 (2%)			1 (2%)	
Atrophy					1 (2%)	1 (2%)
Congestion		1 (2%)				
Cyst				1 (2%)		
Depletion Lymphoid						
Hemorrhage		2 (4%)		1 (2%)		1 (2%)
Hyperplasia	11 (24%)	13 (28%)	10 (21%)	10 (21%)	8 (17%)	1 (2%)
Infiltration Cellular, Histiocytic	3 (7%)	4 (9%)	2 (4%)	1 (2%)		5 (11%)
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic				1 (2%)		
Mineralization						
Pigmentation		1 (2%)			1 (2%)	
Lymph Node, Mesenteric	(45)	(44)	(46)	(44)	(42)	(43)
Angiectasis	22 (49%)	18 (41%)	26 (57%)	22 (50%)	17 (40%)	17 (40%)
Depletion Lymphoid				1 (2%)		
Hematopoietic Cell Proliferation			1 (2%)	2 (5%)		
Hemorrhage		2 (5%)	1 (2%)		2 (5%)	1 (2%)
Hyperplasia	6 (13%)	3 (7%)	11 (24%)	10 (23%)	6 (14%)	
Hyperplasia, Lymphoid			1 (2%)			
Infiltration Cellular, Histiocytic		1 (2%)	3 (7%)	1 (2%)	1 (2%)	2 (5%)
Infiltration Cellular, Lymphocytic						
Infiltration Cellular, Mixed Cell						
Inflammation, Acute	1 (2%)					
Inflammation, Chronic Active	1 (2%)					
Necrosis						
Vein, Thrombosis						1 (2%)
Spleen	(46)	(46)	(48)	(46)	(46)	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:05

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Angiectasis	1 (2%)					
Congestion					1 (2%)	
Hematopoietic Cell Proliferation	22 (48%)	32 (70%)	14 (29%)	12 (26%)	16 (35%)	27 (60%)
Infiltration Cellular, Histiocytic	1 (2%)					
Infiltration Cellular, Lymphocytic						
Inflammation, Chronic Active						
Lymph Follic, Atrophy		2 (4%)		1 (2%)	3 (7%)	1 (2%)
Lymph Follic, Hyperplasia	21 (46%)	11 (24%)	24 (50%)	22 (48%)	19 (41%)	5 (11%)
Metaplasia, Osseous			1 (2%)			
Necrosis						
Pigmentation						
Thymus	(28)	(32)	(34)	(33)	(32)	(35)
Atrophy	13 (46%)	22 (69%)	11 (32%)	13 (39%)	13 (41%)	19 (54%)
Cortex, Hyperplasia						
Cyst	2 (7%)	1 (3%)	3 (9%)	4 (12%)	3 (9%)	2 (6%)
Epithel Cell, Hyperplasia						
Hemorrhage					1 (3%)	
Infiltration Cellular, Mixed Cell						
Medulla, Hyperplasia						
Necrosis						
INTEGUMENTARY SYSTEM						
Mammary Gland	(2)	(1)	(1)	(1)	(2)	(1)
Cyst						1 (100%)
Skin	(46)	(47)	(48)	(47)	(48)	(45)
Edema	1 (2%)	2 (4%)	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Epithelium, Hyperplasia		2 (4%)	1 (2%)		1 (2%)	3 (7%)
Erosion	2 (4%)	1 (2%)				
Fat, Necrosis					1 (2%)	
Inflammation, Acute	1 (2%)					1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:06

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Inflammation, Chronic	2 (4%)	4 (9%)		2 (4%)	3 (6%)	3 (7%)
Inflammation, Chronic Active	2 (4%)	5 (11%)	1 (2%)		3 (6%)	1 (2%)
Metaplasia, Osseous					1 (2%)	
Prepuce, Inflammation, Acute						
Prepuce, Inflammation, Chronic Active					1 (2%)	
Sebaceous GI, Hyperplasia						
Ulcer	2 (4%)	5 (11%)	2 (4%)		3 (6%)	
MUSCULOSKELETAL SYSTEM						
Bone	(47)	(48)	(48)	(48)	(47)	(47)
Calvarium, Hyperostosis					1 (2%)	1 (2%)
Cartilage, Femur, Joint, Degeneration	9 (19%)	9 (19%)	15 (31%)	12 (25%)	9 (19%)	8 (17%)
Cartilage, Sternum, Degeneration						1 (2%)
Cranium, Hyperostosis		1 (2%)	1 (2%)			
Femur, Hyperostosis					1 (2%)	
Femur, Joint, Hyperostosis						
Femur, Joint, Inflammation, Acute		1 (2%)				
Femur, Joint, Inflammation, Chronic						1 (2%)
Femur, Joint, Inflammation, Chronic Active						
Femur, Osteomalacia						
Periosteum, Sternum, Inflammation, Chronic						1 (2%)
Sternum, Hyperostosis					1 (2%)	
Sternum, Inflammation, Acute						1 (2%)
Sternum, Osteomalacia						
Skeletal Muscle	(47)	(48)	(48)	(48)	(48)	(47)
Infiltration Cellular, Lymphocytic	1 (2%)	1 (2%)	2 (4%)	1 (2%)	1 (2%)	
Inflammation, Subacute						
Mineralization						
Necrosis					1 (2%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:06

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Regeneration					1 (2%)	
NERVOUS SYSTEM						
Brain, Cerebellum	(47)	(48)	(47)	(48)	(46)	(46)
Hemorrhage		1 (2%)				
Meninges, Inflammation, Acute						
Meninges, Mineralization				1 (2%)		
Necrosis	1 (2%)					
Brain, Cerebrum	(47)	(48)	(48)	(48)	(48)	(48)
Cyst Epithelial Inclusion						
Inflammation, Acute						
Meninges, Inflammation, Acute				1 (2%)		
Necrosis	1 (2%)					
Thalamus, Mineralization	22 (47%)	23 (48%)	35 (73%)	24 (50%)	26 (54%)	24 (50%)
Peripheral Nerve	(47)	(48)	(47)	(48)	(48)	(47)
Degeneration	6 (13%)	7 (15%)	3 (6%)	3 (6%)	2 (4%)	4 (9%)
Spinal Cord, Thoracic	(47)	(48)	(48)	(48)	(48)	(48)
Meninges, Inflammation, Acute				1 (2%)		
Necrosis		1 (2%)				
RESPIRATORY SYSTEM						
Larynx	(46)	(47)	(46)	(47)	(45)	(47)
Atrophy					1 (2%)	
Cyst		1 (2%)				
Infiltration Cellular, Lymphocytic					1 (2%)	
Inflammation, Acute		1 (2%)		1 (2%)		1 (2%)
Inflammation, Chronic						
Inflammation, Subacute	1 (2%)			1 (2%)		
Lung	(47)	(48)	(48)	(48)	(48)	(48)
Alveolar Epith, Hyperplasia	4 (9%)	6 (13%)	1 (2%)	3 (6%)	7 (15%)	12 (25%)
Bronchiole, Epithelium, Hyperplasia			1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:06

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Foreign Body				1 (2%)		
Hemorrhage				1 (2%)		
Infiltration Cellular, Histiocytic		1 (2%)	1 (2%)			1 (2%)
Infiltration Cellular, Lymphocytic	3 (6%)	2 (4%)	14 (29%)	11 (23%)	4 (8%)	2 (4%)
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic	5 (11%)	1 (2%)	4 (8%)	1 (2%)	1 (2%)	1 (2%)
Inflammation, Chronic Active				1 (2%)		
Parasite Protozoan	1 (2%)		1 (2%)			
Pigmentation	1 (2%)	1 (2%)				
Pleura, Infiltration Cellular, Lymphocytic						
Vein, Inflammation, Acute		1 (2%)				
Vein, Inflammation, Chronic			1 (2%)			
Vein, Inflammation, Subacute						
Nose	(47)	(48)	(48)	(48)	(48)	(46)
Foreign Body						
Glands, Hyperplasia						
Inflammation	1 (2%)	1 (2%)			1 (2%)	
Mucosa, Cyst			1 (2%)			
Nasolacrim Dct, Inflammation, Acute			1 (2%)			
Nasolacrim Dct, Inflammation, Chronic				1 (2%)		
Olfactory Epi, Cytoplasmic Alteration	4 (9%)	7 (15%)	1 (2%)	3 (6%)	3 (6%)	4 (9%)
Respirat Epith, Cytoplasmic Alteration	5 (11%)	3 (6%)	5 (10%)	5 (10%)	8 (17%)	1 (2%)
Trachea	(45)	(48)	(47)	(48)	(48)	(48)
Inflammation, Acute						
SPECIAL SENSES SYSTEM						
Ear	(1)	(0)	(0)	(0)	(0)	(1)
Inflammation, Chronic Active	1 (100%)					
Ulcer	1 (100%)					
Eye	(47)	(46)	(48)	(48)	(48)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:06

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Atrophy	1 (2%)					
Cornea, Degeneration						
Cornea, Hyperplasia					1 (2%)	
Cornea, Inflammation, Acute		3 (7%)	2 (4%)		1 (2%)	2 (4%)
Cornea, Inflammation, Chronic	2 (4%)	5 (11%)		1 (2%)	2 (4%)	4 (9%)
Cornea, Inflammation, Chronic Active	4 (9%)	3 (7%)	1 (2%)		1 (2%)	5 (11%)
Inflammation, Chronic Active						
Iris, Inflammation, Acute						1 (2%)
Lens, Cataract	3 (6%)	6 (13%)		2 (4%)	3 (6%)	4 (9%)
Lids, Inflammation, Chronic Active						
Mineralization	1 (2%)					
Optic Nerve, Inflammation, Acute				1 (2%)		
Harderian Gland	(47)	(48)	(47)	(48)	(48)	(45)
Hyperplasia, Focal	1 (2%)	1 (2%)			2 (4%)	
Infiltration Cellular, Lymphocytic	8 (17%)	6 (13%)	17 (36%)	17 (35%)	19 (40%)	2 (4%)
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic		1 (2%)				
Inflammation, Chronic Active	1 (2%)					
Lacrimal Gland	(45)	(46)	(47)	(47)	(48)	(47)
Amyloid Deposition						1 (2%)
Atrophy	10 (22%)	14 (30%)	6 (13%)	11 (23%)	7 (15%)	10 (21%)
Atrophy, Focal						
Cyst	1 (2%)					
Degeneration				1 (2%)		
Duct, Hyperplasia					1 (2%)	
Hyperplasia, Focal			1 (2%)			
Infiltration Cellular, Lymphocytic	12 (27%)	15 (33%)	16 (34%)	16 (34%)	14 (29%)	11 (23%)
Infiltration Cellular, Mast Cell		1 (2%)				
Infiltration Cellular, Mixed Cell						
Inflammation, Chronic Active	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:06

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Inflammation, Chronic Active Mineralization Necrosis	1 (2%)		1 (2%)			
Zymbal's Gland Cyst Dilatation Hyperplasia Infiltration Cellular, Lymphocytic Inflammation, Subacute	(46)	(43)	(46)	(45)	(47)	(42)
		1 (2%)		1 (2%)		
			1 (2%)			1 (2%)
URINARY SYSTEM						
Kidney	(47)	(47)	(48)	(47)	(48)	(48)
Amyloid Deposition		2 (4%)	4 (8%)	6 (13%)	1 (2%)	1 (2%)
Artery, Inflammation, Chronic Atrophy		1 (2%)			1 (2%)	
Atrophy, Focal						1 (2%)
Bacterium		1 (2%)		1 (2%)		
Cyst	3 (6%)	3 (6%)	7 (15%)	3 (6%)	4 (8%)	4 (8%)
Glomerulosclerosis	34 (72%)	34 (72%)	44 (92%)	33 (70%)	34 (71%)	29 (60%)
Glomerulus, Thrombosis						
Hematopoietic Cell Proliferation						
Hypoplasia, Focal		1 (2%)	1 (2%)			
Infarct				1 (2%)	1 (2%)	1 (2%)
Infiltration Cellular, Lymphocytic	19 (40%)	14 (30%)	31 (65%)	27 (57%)	25 (52%)	15 (31%)
Infiltration Cellular, Mixed Cell Inflammation, Acute						
Inflammation, Chronic	1 (2%)			1 (2%)	1 (2%)	
Inflammation, Chronic Active					1 (2%)	
Metaplasia, Osseous				1 (2%)		
Mineralization	8 (17%)	4 (9%)	5 (10%)	9 (19%)	4 (8%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:07

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Nephropathy		1 (2%)				
Papilla, Necrosis		1 (2%)				
Pelvis, Dilatation	2 (4%)	2 (4%)		1 (2%)	1 (2%)	1 (2%)
Pelvis, Inflammation						
Pelvis, Inflammation, Acute	1 (2%)				1 (2%)	
Pelvis, Inflammation, Chronic		1 (2%)			1 (2%)	
Pelvis, Inflammation, Chronic Active	1 (2%)	1 (2%)			1 (2%)	
Pelvis, Inflammation, Subacute						
Pelvis, Mineralization						
Pigmentation						
Renal Tubule, Accumulation, Hyaline Droplet					2 (4%)	2 (4%)
Renal Tubule, Degeneration	16 (34%)	6 (13%)	17 (35%)	20 (43%)	11 (23%)	8 (17%)
Renal Tubule, Hyperplasia, Focal	2 (4%)	3 (6%)	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Renal Tubule, Necrosis		1 (2%)				
Vein, Thrombosis						
Ureter	(1)	(0)	(0)	(0)	(0)	(0)
Urethra	(0)	(0)	(0)	(1)	(3)	(0)
Bulboureth GI, Congestion						
Bulboureth GI, Inflammation, Acute					2 (67%)	
Urinary Bladder	(45)	(46)	(48)	(47)	(48)	(45)
Calculus Gross Observation					1 (2%)	
Dilatation	1 (2%)	1 (2%)			1 (2%)	1 (2%)
Edema	1 (2%)	4 (9%)				1 (2%)
Infiltration Cellular, Lymphocytic	19 (42%)	17 (37%)	27 (56%)	24 (51%)	17 (35%)	23 (51%)
Infiltration Cellular, Mixed Cell						
Inflammation, Acute		1 (2%)			2 (4%)	1 (2%)
Inflammation, Chronic		1 (2%)				
Inflammation, Chronic Active	1 (2%)	1 (2%)			2 (4%)	
Mineralization						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:13:07
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse MALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Transit Epithe, Hyperplasia	1 (2%)					
Ulcer	1 (2%)					2 (4%)

END OF MALE DATA

Experiment Number: 00602-05
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
 Test Compound: Urethane + ethanol (combination)
 CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
 Time Report Requested: 00:13:07
 First Dose M/F: NA / NA
 Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	47
Early Deaths						
Drowned					4	3
Moribund	1	3	4	14	1	2
Natural Death	5	7	13	22	2	7
Survivors						
Moribund			1	4		2
Natural Death	4	1	3	7	2	
Terminal Sacrifice	38	37	27	1	39	33
Animals Examined Microscopically	48	48	48	48	47	47
ALIMENTARY SYSTEM						
Esophagus	(48)	(47)	(47)	(47)	(47)	(47)
Autolysis				2 (4%)		
Gallbladder	(47)	(45)	(46)	(43)	(47)	(45)
Autolysis	7 (15%)	1 (2%)	2 (4%)	7 (16%)		2 (4%)
Epithelium, Cytoplasmic Alteration	1 (2%)					
Infiltration Cellular, Lymphocytic		1 (2%)			1 (2%)	
Inflammation, Chronic Active	1 (2%)					
Intestine Large	(0)	(0)	(0)	(0)	(0)	(0)
Inflammation						
Intestine Large, Cecum	(48)	(45)	(46)	(45)	(47)	(45)
Autolysis	5 (10%)	1 (2%)	3 (7%)	15 (33%)	1 (2%)	1 (2%)
Lymphoid Tiss, Hyperplasia			1 (2%)		1 (2%)	1 (2%)
Intestine Large, Colon	(48)	(44)	(46)	(46)	(47)	(45)
Autolysis	5 (10%)	1 (2%)	3 (7%)	15 (33%)	1 (2%)	1 (2%)
Inflammation, Chronic						1 (2%)
Inflammation, Chronic Active						
Lymphoid Tiss, Hyperplasia						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:07

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Intestine Large, Rectum	(48)	(45)	(45)	(46)	(47)	(44)
Autolysis	1 (2%)		1 (2%)	11 (24%)	1 (2%)	1 (2%)
Inflammation						
Polyarteritis						
Intestine Small	(0)	(1)	(0)	(0)	(0)	(0)
Intussusception		1 (100%)				
Intestine Small, Duodenum	(48)	(43)	(44)	(44)	(47)	(45)
Autolysis	8 (17%)	2 (5%)	2 (5%)	18 (41%)	2 (4%)	1 (2%)
Infiltration Cellular, Lymphocytic		1 (2%)				
Lymphoid Tiss, Hyperplasia				1 (2%)		1 (2%)
Intestine Small, Ileum	(48)	(44)	(46)	(44)	(47)	(45)
Autolysis	8 (17%)	2 (5%)	3 (7%)	18 (41%)	2 (4%)	1 (2%)
Intussusception						
Lymphoid Tiss, Hyperplasia	1 (2%)	4 (9%)	4 (9%)		2 (4%)	1 (2%)
Intestine Small, Jejunum	(48)	(44)	(46)	(44)	(47)	(45)
Angiectasis						
Autolysis	8 (17%)	2 (5%)	3 (7%)	18 (41%)	2 (4%)	1 (2%)
Lymphoid Tiss, Hyperplasia		1 (2%)	1 (2%)		1 (2%)	1 (2%)
Liver	(48)	(47)	(47)	(47)	(47)	(47)
Accessory Spleen					1 (2%)	
Angiectasis		3 (6%)	10 (21%)	24 (51%)	2 (4%)	5 (11%)
Autolysis				2 (4%)	3 (6%)	1 (2%)
Basophilic Focus	1 (2%)	1 (2%)	1 (2%)		2 (4%)	
Caudate Lobe, Infarct					1 (2%)	
Centrilobular, Necrosis	1 (2%)	2 (4%)		2 (4%)		
Centrilobular, Pigmentation						
Clear Cell Focus	1 (2%)	2 (4%)				
Clear Cell Focus, Multiple				1 (2%)		
Degeneration, Cystic		1 (2%)				
Eosinophilic Focus	2 (4%)	8 (17%)	5 (11%)		2 (4%)	10 (21%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:08

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Eosinophilic Focus	2 (4%)	8 (17%)	5 (11%)		2 (4%)	10 (21%)
Eosinophilic Focus, Multiple	1 (2%)	6 (13%)	27 (57%)	20 (43%)		10 (21%)
Fatty Change						
Fatty Change, Focal						1 (2%)
Fibrosis						1 (2%)
Granuloma, Focal	4 (8%)	1 (2%)			2 (4%)	
Hematopoietic Cell Proliferation	7 (15%)	6 (13%)	20 (43%)	19 (40%)	3 (6%)	16 (34%)
Hematopoietic Cell Proliferation Granulocytic		1 (2%)				
Hepatocyte, Necrosis	2 (4%)					1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	7 (15%)	10 (21%)	4 (9%)	5 (11%)	11 (23%)	8 (17%)
Hepatodiaphragmatic Nodule						
Infiltration Cellular, Lymphocytic	12 (25%)	16 (34%)	10 (21%)	1 (2%)	15 (32%)	12 (26%)
Inflammation						1 (2%)
Inflammation, Chronic						
Inflammation, Chronic Active	1 (2%)	2 (4%)	1 (2%)		2 (4%)	1 (2%)
Inflammation, Granulomatous					1 (2%)	
Kupffer Cell, Hyperplasia		1 (2%)	1 (2%)			1 (2%)
Leukocytosis						
Median Lobe, Infarct						
Mixed Cell Focus		5 (11%)	1 (2%)			1 (2%)
Mixed Cell Focus, Multiple		1 (2%)		1 (2%)		5 (11%)
Necrosis	1 (2%)	2 (4%)	5 (11%)	11 (23%)	5 (11%)	2 (4%)
Oval Cell, Hyperplasia	1 (2%)		1 (2%)			
Pigmentation				1 (2%)		1 (2%)
Regeneration			1 (2%)	2 (4%)		
Thrombosis		1 (2%)	1 (2%)	11 (23%)	1 (2%)	
Mesentery	(3)	(4)	(7)	(6)	(2)	(5)
Fat, Inflammation				1 (17%)		
Fat, Necrosis	3 (100%)	4 (100%)	6 (86%)	3 (50%)	2 (100%)	3 (60%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:08

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Fibrosis						
Pancreas	(48)	(43)	(47)	(44)	(47)	(45)
Acinar Cell, Atrophy	1 (2%)	1 (2%)	2 (4%)			
Acinar Cell, Vacuolization Cytoplasmic			1 (2%)			
Angiectasis					1 (2%)	
Autolysis			1 (2%)	9 (20%)		
Cyst					1 (2%)	
Duct, Cyst						1 (2%)
Hemorrhage						
Infiltration Cellular, Lymphocytic	12 (25%)	15 (35%)	11 (23%)	3 (7%)	14 (30%)	18 (40%)
Inflammation, Chronic						1 (2%)
Necrosis		1 (2%)				
Salivary Glands	(48)	(48)	(48)	(47)	(47)	(47)
Atrophy		1 (2%)		3 (6%)		
Autolysis				1 (2%)		
Fibrosis						1 (2%)
Hemorrhage				1 (2%)		
Infiltration Cellular, Lymphocytic	37 (77%)	42 (88%)	37 (77%)	19 (40%)	43 (91%)	38 (81%)
Inflammation						
Parenchym Cell, Hypertrophy						
Stomach	(0)	(0)	(0)	(0)	(0)	(0)
Stomach, Forestomach	(48)	(46)	(46)	(46)	(47)	(46)
Autolysis	1 (2%)		1 (2%)	9 (20%)	1 (2%)	1 (2%)
Cyst Epithelial Inclusion		1 (2%)				
Epithelium, Hyperplasia	6 (13%)	11 (24%)	10 (22%)	9 (20%)	4 (9%)	4 (9%)
Foreign Body			2 (4%)			
Hyperkeratosis	2 (4%)		2 (4%)	1 (2%)		
Infiltration Cellular, Lymphocytic		1 (2%)		1 (2%)		1 (2%)
Inflammation	1 (2%)	2 (4%)	7 (15%)	2 (4%)	1 (2%)	1 (2%)
Ulcer	1 (2%)	1 (2%)	1 (2%)		1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:08

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Ulcer	1 (2%)	1 (2%)	1 (2%)		1 (2%)	1 (2%)
Stomach, Glandular	(47)	(46)	(46)	(47)	(47)	(46)
Autolysis	1 (2%)		1 (2%)	9 (19%)	1 (2%)	1 (2%)
Cyst						
Diverticulum			1 (2%)			
Epithelium, Hyperplasia			1 (2%)			
Epithelium, Hypertrophy				1 (2%)		
Infiltration Cellular, Lymphocytic				1 (2%)		1 (2%)
Inflammation						
Metaplasia, Squamous						
Mineralization				1 (2%)		
Thrombosis				1 (2%)		
Tongue	(48)	(48)	(48)	(46)	(47)	(47)
Polyarteritis				1 (2%)	1 (2%)	
CARDIOVASCULAR SYSTEM						
Blood Vessel	(47)	(47)	(48)	(46)	(47)	(47)
Infiltration Cellular, Lymphocytic				1 (2%)		
Inflammation						
Mineralization		1 (2%)				
Heart	(48)	(48)	(48)	(48)	(47)	(47)
Abscess						1 (2%)
Angiectasis				1 (2%)		
Artery, Hypertrophy					1 (2%)	
Artery, Inflammation				1 (2%)		
Atrium, Inflammation						
Atrium, Thrombosis				2 (4%)		1 (2%)
Av Valve, Inflammation				1 (2%)		
Cardiomyopathy	2 (4%)	2 (4%)	5 (10%)	4 (8%)	2 (4%)	4 (9%)
Embolus Tumor						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:08

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Endothelium, Hyperplasia	1 (2%)		3 (6%)	6 (13%)		
Epicardium, Inflammation, Chronic Mineralization		1 (2%)	1 (2%)	4 (8%)	1 (2%)	1 (2%)
Myocardium, Inflammation			1 (2%)	2 (4%)		
Myocardium, Inflammation, Chronic				1 (2%)		
Myocardium, Thrombosis			1 (2%)			
Necrosis				2 (4%)		
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(0)	(0)	(1)	(0)	(0)
Parenchym Cell, Hyperplasia				1 (100%)		
Adrenal Gland, Cortex	(48)	(45)	(45)	(47)	(46)	(47)
Accessory Adrenal Cortical Nodule	1 (2%)					
Angiectasis	1 (2%)	1 (2%)		1 (2%)	1 (2%)	1 (2%)
Atrophy			1 (2%)	1 (2%)		
Autolysis				4 (9%)		
Cyst						1 (2%)
Hematopoietic Cell Proliferation		1 (2%)	1 (2%)	2 (4%)		
Hemorrhage						
Hypertrophy	1 (2%)					
Infarct						1 (2%)
Infiltration Cellular, Lymphocytic			1 (2%)	3 (6%)		
Inflammation						
Inflammation, Acute			1 (2%)			
Pigmentation						
Subcapsular, Hyperplasia	45 (94%)	36 (80%)	33 (73%)	29 (62%)	42 (91%)	37 (79%)
Thrombosis		1 (2%)			1 (2%)	
Vacuolization Cytoplasmic						
Adrenal Gland, Medulla	(47)	(42)	(43)	(47)	(45)	(47)
Angiectasis				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:08

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Autolysis				4 (9%)		
Hemorrhage						
Hyperplasia	1 (2%)	1 (2%)	2 (5%)			1 (2%)
Islets, Pancreatic	(48)	(43)	(47)	(44)	(47)	(45)
Autolysis			1 (2%)	7 (16%)		
Hyperplasia	2 (4%)	6 (14%)	5 (11%)	4 (9%)	7 (15%)	2 (4%)
Infiltration Cellular, Lymphocytic		1 (2%)	1 (2%)		2 (4%)	2 (4%)
Inflammation						1 (2%)
Parathyroid Gland	(32)	(38)	(31)	(40)	(34)	(37)
Autolysis				2 (5%)		
Cyst						
Infiltration Cellular, Lymphocytic		1 (3%)				
Inflammation	1 (3%)					
Pituitary Gland	(42)	(42)	(40)	(39)	(44)	(41)
Angiectasis	3 (7%)	5 (12%)			1 (2%)	1 (2%)
Cyst						2 (5%)
Hemorrhage						
Pars Distalis, Hyperplasia	5 (12%)	1 (2%)	3 (8%)		1 (2%)	2 (5%)
Thyroid Gland	(47)	(47)	(47)	(45)	(46)	(47)
Autolysis				4 (9%)		
C Cell, Hyperplasia	1 (2%)		1 (2%)		1 (2%)	
Cyst						
Cyst Multilocular			3 (6%)		2 (4%)	
Depletion Secretory						
Follicular Cel, Hyperplasia	1 (2%)			1 (2%)	1 (2%)	
Infiltration Cellular, Lymphocytic	2 (4%)			1 (2%)	1 (2%)	2 (4%)
Infiltration Cellular, Polymorphnuclr			1 (2%)			
Inflammation				1 (2%)		

GENERAL BODY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:09

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Tissue NOS	(1)	(1)	(1)	(4)	(0)	(1)
Abdominal, Cyst						
Abdominal, Fat, Necrosis						
Abdominal, Inflammation						
GENITAL SYSTEM						
Clitoral Gland	(43)	(41)	(43)	(37)	(40)	(40)
Atrophy	39 (91%)	39 (95%)	40 (93%)	32 (86%)	37 (93%)	38 (95%)
Autolysis			1 (2%)			
Dilatation						
Infiltration Cellular, Lymphocytic						
Pigmentation						1 (3%)
Ovary	(48)	(46)	(46)	(39)	(47)	(46)
Angiectasis	2 (4%)	2 (4%)	6 (13%)	6 (15%)		2 (4%)
Atrophy	42 (88%)	40 (87%)	37 (80%)	30 (77%)	45 (96%)	40 (87%)
Autolysis	1 (2%)			2 (5%)		
Congestion						
Cyst	10 (21%)	11 (24%)	12 (26%)	2 (5%)	14 (30%)	12 (26%)
Hematocyst	9 (19%)	4 (9%)	3 (7%)	2 (5%)	6 (13%)	6 (13%)
Hemorrhage			1 (2%)			1 (2%)
Hyperplasia, Tubular			3 (7%)	4 (10%)		1 (2%)
Infiltration Cellular, Histiocytic		1 (2%)		1 (3%)		1 (2%)
Infiltration Cellular, Lymphocytic		1 (2%)				
Inflammation	1 (2%)					
Metaplasia, Osseous					1 (2%)	
Mineralization				2 (5%)		1 (2%)
Periovarn Tiss, Cyst	2 (4%)			1 (3%)	1 (2%)	
Periovarn Tiss, Infiltration Cellular, Lymphocytic						
Periovarn Tiss, Inflammation						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:09

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Periovarn Tiss, Thrombosis				1 (3%)		
Pigmentation		1 (2%)				1 (2%)
Polyarteritis						
Thrombosis			4 (9%)	1 (3%)		2 (4%)
Uterus	(48)	(47)	(48)	(46)	(47)	(47)
Amyloid Deposition		1 (2%)				
Angiectasis		4 (9%)	6 (13%)	7 (15%)	1 (2%)	2 (4%)
Atrophy						
Autolysis				1 (2%)		
Cervix, Hemorrhage						
Dilatation	2 (4%)					
Endometrium, Hyperplasia, Cystic Hemorrhage	45 (94%)	39 (83%)	34 (71%)	28 (61%)	42 (89%)	40 (85%)
Infiltration Cellular, Histiocytic			1 (2%)			
Infiltration Cellular, Polymorphnuclr		1 (2%)				
Inflammation		1 (2%)	2 (4%)			1 (2%)
Inflammation, Suppurative						
Mineralization			1 (2%)			
Pigmentation			1 (2%)			
Thrombosis		1 (2%)	4 (8%)	4 (9%)		
Vacuolization Cytoplasmic	1 (2%)					
Vagina	(48)	(47)	(46)	(43)	(47)	(47)
Autolysis				1 (2%)		
Exudate		2 (4%)			2 (4%)	2 (4%)
Hemorrhage						
Inflammation	1 (2%)	1 (2%)			1 (2%)	1 (2%)
Polyarteritis						
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(47)	(46)	(47)	(47)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:09

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Angiectasis				2 (4%)		
Autolysis				4 (9%)		
Infiltration Cellular, Histiocytic						
Myeloid Cell, Hyperplasia	8 (17%)	4 (9%)	5 (11%)	7 (15%)		2 (4%)
Pigmentation			1 (2%)		1 (2%)	
Lymph Node	(6)	(4)	(9)	(12)	(1)	(8)
Hematocyst						
Lumbar, Autolysis				1 (8%)		
Lumbar, Hematopoietic Cell Proliferation						
Lumbar, Hemorrhage			1 (11%)		1 (100%)	
Lumbar, Hyperplasia				1 (8%)	1 (100%)	
Lumbar, Infiltration Cellular, Histiocytic				1 (8%)		
Lumbar, Infiltration Cellular, Plasma Cell						
Lumbar, Infiltration Cellular, Polymorphnuclr						
Lumbar, Inflammation			1 (11%)			
Mediastinal, Hyperplasia			1 (11%)			
Pigmentation						
Renal, Hematopoietic Cell Proliferation						
Renal, Hyperplasia			1 (11%)	1 (8%)		1 (13%)
Renal, Infiltration Cellular, Polymorphnuclr		1 (25%)				
Thoracic, Autolysis						
Thoracic, Hyperplasia						
Lymph Node, Mandibular	(45)	(47)	(45)	(42)	(47)	(44)
Atrophy	1 (2%)			1 (2%)		
Autolysis				3 (7%)		
Hematopoietic Cell Proliferation		1 (2%)				
Hemorrhage	1 (2%)			3 (7%)	1 (2%)	
Hyperplasia	1 (2%)	5 (11%)	4 (9%)	2 (5%)	4 (9%)	5 (11%)
Hyperplasia, Plasma Cell		1 (2%)				
Infiltration Cellular, Histiocytic	1 (2%)			2 (5%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:09

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Infiltration Cellular, Histiocytic	1 (2%)			2 (5%)		
Infiltration Cellular, Plasma Cell						
Inflammation						
Lymph Node, Mesenteric	(47)	(45)	(42)	(39)	(43)	(42)
Angiectasis	1 (2%)		2 (5%)	1 (3%)	1 (2%)	1 (2%)
Atrophy	1 (2%)			3 (8%)		
Autolysis	1 (2%)			1 (3%)		
Cyst		1 (2%)				
Hematopoietic Cell Proliferation	1 (2%)			2 (5%)		
Hemorrhage	1 (2%)		1 (2%)	1 (3%)		
Hyperplasia	2 (4%)	4 (9%)	1 (2%)	1 (3%)	5 (12%)	2 (5%)
Infiltration Cellular, Histiocytic			1 (2%)	1 (3%)		
Infiltration Cellular, Polymorphnuclr		1 (2%)				
Inflammation, Granulomatous					1 (2%)	
Pigmentation						
Spleen	(48)	(45)	(47)	(46)	(47)	(46)
Angiectasis		1 (2%)		1 (2%)	2 (4%)	1 (2%)
Autolysis				7 (15%)		
Capsule, Inflammation						1 (2%)
Hematopoietic Cell Proliferation	4 (8%)	8 (18%)	15 (32%)	21 (46%)	2 (4%)	8 (17%)
Hematopoietic Cell Proliferation Granulocytic						1 (2%)
Hemorrhage						
Infiltration Cellular, Histiocytic				1 (2%)		
Lymph Follic, Hyperplasia	15 (31%)	26 (58%)	14 (30%)	1 (2%)	25 (53%)	16 (35%)
Pigmentation		1 (2%)		1 (2%)	3 (6%)	1 (2%)
Polyarteritis				1 (2%)		
Red Pulp, Atrophy						
Thrombosis				1 (2%)		
Thymus	(40)	(37)	(32)	(38)	(41)	(40)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:09

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Atrophy	9 (23%)	3 (8%)	5 (16%)	9 (24%)	2 (5%)	6 (15%)
Autolysis	2 (5%)			3 (8%)		
Cyst						
Hemorrhage						
Hyperplasia	3 (8%)	4 (11%)	3 (9%)		4 (10%)	6 (15%)
INTEGUMENTARY SYSTEM						
Mammary Gland	(47)	(46)	(46)	(48)	(47)	(45)
Autolysis			1 (2%)			
Duct, Ectasia	2 (4%)		1 (2%)		1 (2%)	
Hyperplasia	2 (4%)	3 (7%)		1 (2%)	2 (4%)	
Infiltration Cellular, Lymphocytic		1 (2%)	1 (2%)	1 (2%)		
Lactation	3 (6%)	3 (7%)	2 (4%)		3 (6%)	2 (4%)
Skin	(48)	(48)	(46)	(48)	(47)	(47)
Autolysis			1 (2%)	1 (2%)		
Cyst Epithelial Inclusion						
Fat, Necrosis						
Fibrosis		1 (2%)				
Hemorrhage				1 (2%)		
Inflammation	1 (2%)			2 (4%)		
Inflammation, Chronic						
Neovascularization				1 (2%)		
Sebaceous GI, Distended						
Thrombosis				1 (2%)		
Ulcer		1 (2%)	1 (2%)			
MUSCULOSKELETAL SYSTEM						
Bone	(48)	(48)	(48)	(48)	(46)	(47)
Cartilage, Sternum, Degeneration	1 (2%)			1 (2%)		
Femur, Angiectasis		1 (2%)				
Femur, Fibrous Osteodystrophy	9 (19%)	8 (17%)	5 (10%)	3 (6%)	7 (15%)	5 (11%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:10

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Sternum, Angiectasis		1 (2%)				
Sternum, Autolysis						
Sternum, Fibrous Osteodystrophy	30 (63%)	22 (46%)	22 (46%)	6 (13%)	19 (41%)	20 (43%)
Skeletal Muscle	(48)	(48)	(48)	(48)	(47)	(47)
Autolysis				1 (2%)		
Degeneration						
Diaphragm, Hyperplasia		1 (2%)				
Infiltration Cellular, Lymphocytic						
Mineralization						
NERVOUS SYSTEM						
Brain	(0)	(0)	(0)	(0)	(0)	(0)
Brain, Brain Stem	(0)	(0)	(0)	(0)	(0)	(0)
Hemorrhage						
Brain, Cerebellum	(48)	(48)	(48)	(48)	(47)	(46)
Abscess						
Autolysis				1 (2%)		
Hemorrhage						1 (2%)
Meninges, Inflammation, Chronic Active		1 (2%)				
Thalamus, Mineralization	1 (2%)					
Brain, Cerebrum	(48)	(48)	(48)	(48)	(47)	(47)
Autolysis				1 (2%)		
Granuloma				2 (4%)		
Hemorrhage			1 (2%)	2 (4%)		
Hypothalamus, Compression	1 (2%)					
Inflammation						
Meninges, Inflammation						
Meninges, Inflammation, Chronic Active		1 (2%)				
Necrosis				1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:10

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMURE
Perivascular, Infiltration Cellular, Lymphocytic						
Thalamus, Mineralization	21 (44%)	26 (54%)	26 (54%)	26 (54%)	29 (62%)	29 (62%)
Peripheral Nerve	(48)	(47)	(48)	(48)	(47)	(46)
Autolysis				1 (2%)		
Spinal Cord	(0)	(0)	(0)	(0)	(0)	(0)
Spinal Cord, Thoracic	(48)	(48)	(48)	(48)	(47)	(47)
Autolysis				2 (4%)		
Hemorrhage			1 (2%)			
RESPIRATORY SYSTEM						
Larynx	(48)	(46)	(46)	(45)	(47)	(46)
Autolysis				2 (4%)		
Hemorrhage						
Inflammation						
Lung	(48)	(48)	(48)	(47)	(47)	(47)
Alveolar Epith, Hyperplasia		2 (4%)	4 (8%)	7 (15%)	1 (2%)	
Alveolus, Exudate						
Arteriole, Hypertrophy						
Autolysis					3 (6%)	
Congestion				1 (2%)		3 (6%)
Crystals						1 (2%)
Hemorrhage	2 (4%)	5 (10%)	9 (19%)	2 (4%)	7 (15%)	12 (26%)
Infiltration Cellular, Histiocytic		2 (4%)	6 (13%)	6 (13%)	1 (2%)	1 (2%)
Infiltration Cellular, Lymphocytic	34 (71%)	28 (58%)	18 (38%)	11 (23%)	24 (51%)	26 (55%)
Inflammation, Chronic Active	1 (2%)		1 (2%)			1 (2%)
Inflammation, Suppurative						
Leukocytosis						
Pigmentation					1 (2%)	
Nose	(48)	(48)	(48)	(46)	(47)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:10

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Autolysis				2 (4%)		
Fibrous Osteodystrophy	8 (17%)					
Hemorrhage						
Inflammation	1 (2%)					
Trachea	(48)	(47)	(47)	(46)	(47)	(47)
Autolysis				2 (4%)		
Glands, Ectasia						
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Eye	(48)	(47)	(46)	(48)	(47)	(45)
Atrophy			1 (2%)	2 (4%)		
Autolysis	1 (2%)	1 (2%)		1 (2%)		
Bilateral, Phthisis Bulbi				1 (2%)		
Cornea, Inflammation		3 (6%)	6 (13%)	10 (21%)	1 (2%)	3 (7%)
Hemorrhage						
Infiltration Cellular, Lymphocytic						
Lens, Cataract			1 (2%)	1 (2%)		
Phthisis Bulbi		1 (2%)	2 (4%)	3 (6%)	1 (2%)	
Harderian Gland	(48)	(48)	(48)	(48)	(47)	(47)
Atrophy						1 (2%)
Autolysis				1 (2%)		
Dilatation			1 (2%)			
Hyperplasia					2 (4%)	
Infiltration Cellular, Lymphocytic	18 (38%)	11 (23%)	8 (17%)	4 (8%)	10 (21%)	10 (21%)
Inflammation						1 (2%)
Inflammation, Chronic						
Necrosis						1 (2%)
Lacrimal Gland	(45)	(47)	(43)	(40)	(45)	(45)
Atrophy		4 (9%)	2 (5%)		4 (9%)	4 (9%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:10

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Autolysis				1 (3%)		
Cyst	1 (2%)					1 (2%)
Duct, Dilatation		2 (4%)	1 (2%)		1 (2%)	4 (9%)
Hemorrhage				1 (3%)		
Infiltration Cellular, Lymphocytic Inflammation	26 (58%)	32 (68%)	20 (47%)	16 (40%)	25 (56%)	28 (62%)
Parenchym Cell, Hypertrophy	1 (2%)					
Vacuolization Cytoplasmic			1 (2%)			
Zymbal's Gland	(46)	(43)	(46)	(46)	(46)	(43)
Atrophy				1 (2%)		
Autolysis				1 (2%)		
Hyperplasia			1 (2%)			
Infiltration Cellular, Lymphocytic Inflammation, Chronic						1 (2%)
						1 (2%)
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(48)	(47)	(47)
Accumulation, Hyaline Droplet		1 (2%)	1 (2%)	2 (4%)		1 (2%)
Amyloid Deposition			1 (2%)		1 (2%)	
Autolysis	1 (2%)	1 (2%)	1 (2%)	4 (8%)	2 (4%)	
Casts	1 (2%)			2 (4%)		
Congestion			1 (2%)			
Cyst	1 (2%)					
Embolus Bacterial						1 (2%)
Glomerulosclerosis			1 (2%)	2 (4%)	2 (4%)	
Hematopoietic Cell Proliferation						
Hydronephrosis		2 (4%)		1 (2%)		
Infarct	3 (6%)			1 (2%)		1 (2%)
Infiltration Cellular, Lymphocytic	16 (33%)	20 (42%)	15 (31%)	16 (33%)	18 (38%)	14 (30%)
Infiltration Cellular, Plasma Cell						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:10

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	0% ETH/ 0PPM URE	0% ETH/ 10PPMURE	0% ETH/ 30PPMURE	0% ETH/ 90PPMURE	2.5%ETH/0PPM URE	2.5%ETH/10PPMUR E
Infiltration Cellular, Polymorphnuclr			1 (2%)			
Inflammation						1 (2%)
Metaplasia, Osseous	1 (2%)		1 (2%)	1 (2%)	1 (2%)	
Mineralization		1 (2%)	1 (2%)	2 (4%)		
Nephropathy						1 (2%)
Papilla, Necrosis						
Polyarteritis				1 (2%)		
Regeneration						
Renal Tubule, Atrophy				1 (2%)		
Renal Tubule, Degeneration, Focal	1 (2%)					
Renal Tubule, Pigmentation			1 (2%)			
Urinary Bladder	(48)	(46)	(45)	(41)	(45)	(43)
Autolysis	3 (6%)	2 (4%)	1 (2%)	1 (2%)		
Distended	1 (2%)					
Fibrosis						
Infiltration Cellular, Lymphocytic	25 (52%)	28 (61%)	23 (51%)	13 (32%)	29 (64%)	21 (49%)
Polyarteritis						
Ulcer						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:10

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Disposition Summary						
Animals Initially In Study	48	48	48	48	48	48
Early Deaths						
Drowned			4	2		
Moribund	11	7	2	1	3	8
Natural Death	16	25	5	8	13	26
Survivors						
Moribund		2	4	3	1	3
Natural Death	2	6	2	2	4	7
Terminal Sacrifice	19	8	31	32	27	4
Animals Examined Microscopically	48	48	48	48	48	48
ALIMENTARY SYSTEM						
Esophagus	(47)	(47)	(47)	(48)	(47)	(46)
Autolysis	1 (2%)			1 (2%)		
Gallbladder	(46)	(43)	(47)	(44)	(47)	(45)
Autolysis	2 (4%)	4 (9%)	2 (4%)	1 (2%)	2 (4%)	4 (9%)
Epithelium, Cytoplasmic Alteration						
Infiltration Cellular, Lymphocytic	1 (2%)		1 (2%)	1 (2%)		
Inflammation, Chronic Active						
Intestine Large	(0)	(0)	(1)	(0)	(6)	(0)
Inflammation			1 (100%)			
Intestine Large, Cecum	(47)	(41)	(47)	(44)	(42)	(42)
Autolysis	3 (6%)	10 (24%)	3 (6%)	2 (5%)	5 (12%)	4 (10%)
Lymphoid Tiss, Hyperplasia	1 (2%)					
Intestine Large, Colon	(47)	(42)	(47)	(45)	(41)	(42)
Autolysis	3 (6%)	9 (21%)	3 (6%)	2 (4%)	4 (10%)	4 (10%)
Inflammation, Chronic						
Inflammation, Chronic Active	1 (2%)					
Lymphoid Tiss, Hyperplasia	1 (2%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:11

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Intestine Large, Rectum	(47)	(46)	(48)	(47)	(39)	(44)
Autolysis	2 (4%)	7 (15%)	3 (6%)	3 (6%)	3 (8%)	3 (7%)
Inflammation					1 (3%)	
Polyarteritis				1 (2%)		
Intestine Small	(0)	(0)	(0)	(0)	(6)	(0)
Intussusception						
Intestine Small, Duodenum	(47)	(39)	(47)	(44)	(38)	(40)
Autolysis	4 (9%)	8 (21%)	5 (11%)	2 (5%)	5 (13%)	5 (13%)
Infiltration Cellular, Lymphocytic						
Lymphoid Tiss, Hyperplasia						
Intestine Small, Ileum	(47)	(40)	(47)	(44)	(41)	(40)
Autolysis	4 (9%)	9 (23%)	5 (11%)	2 (5%)	6 (15%)	6 (15%)
Intussusception				1 (2%)		
Lymphoid Tiss, Hyperplasia	1 (2%)				2 (5%)	
Intestine Small, Jejunum	(47)	(39)	(47)	(44)	(40)	(40)
Angiectasis		1 (3%)				
Autolysis	3 (6%)	8 (21%)	5 (11%)	2 (5%)	6 (15%)	6 (15%)
Lymphoid Tiss, Hyperplasia	1 (2%)			2 (5%)	1 (3%)	1 (3%)
Liver	(47)	(46)	(48)	(47)	(48)	(48)
Accessory Spleen						
Angiectasis	7 (15%)	20 (43%)	2 (4%)	1 (2%)	5 (10%)	22 (46%)
Autolysis	1 (2%)		1 (2%)	1 (2%)	2 (4%)	1 (2%)
Basophilic Focus			1 (2%)			
Caudate Lobe, Infarct	1 (2%)				1 (2%)	
Centrilobular, Necrosis				1 (2%)		2 (4%)
Centrilobular, Pigmentation					1 (2%)	
Clear Cell Focus	1 (2%)					
Clear Cell Focus, Multiple	1 (2%)					
Degeneration, Cystic						
Eosinophilic Focus	1 (2%)	6 (13%)	2 (4%)	12 (26%)	4 (8%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:11

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Eosinophilic Focus	1 (2%)	6 (13%)	2 (4%)	12 (26%)	4 (8%)	1 (2%)
Eosinophilic Focus, Multiple	20 (43%)	22 (48%)		14 (30%)	21 (44%)	20 (42%)
Fatty Change		1 (2%)				
Fatty Change, Focal						
Fibrosis						
Granuloma, Focal	2 (4%)		2 (4%)	1 (2%)		
Hematopoietic Cell Proliferation	13 (28%)	26 (57%)	3 (6%)	11 (23%)	18 (38%)	27 (56%)
Hematopoietic Cell Proliferation Granulocytic						
Hepatocyte, Necrosis	1 (2%)					
Hepatocyte, Vacuolization Cytoplasmic	7 (15%)	5 (11%)		7 (15%)	10 (21%)	3 (6%)
Hepatodiaphragmatic Nodule			1 (2%)			
Infiltration Cellular, Lymphocytic	5 (11%)	3 (7%)	14 (29%)	8 (17%)	4 (8%)	4 (8%)
Inflammation					1 (2%)	
Inflammation, Chronic				1 (2%)		
Inflammation, Chronic Active		1 (2%)				1 (2%)
Inflammation, Granulomatous						
Kupffer Cell, Hyperplasia				1 (2%)		
Leukocytosis						1 (2%)
Median Lobe, Infarct		1 (2%)				
Mixed Cell Focus			1 (2%)	1 (2%)		
Mixed Cell Focus, Multiple	5 (11%)	3 (7%)		4 (9%)	9 (19%)	2 (4%)
Necrosis	4 (9%)	18 (39%)		1 (2%)	3 (6%)	15 (31%)
Oval Cell, Hyperplasia						
Pigmentation			1 (2%)			
Regeneration		2 (4%)				3 (6%)
Thrombosis	4 (9%)	9 (20%)			1 (2%)	8 (17%)
Mesentery	(6)	(6)	(3)	(3)	(5)	(4)
Fat, Inflammation						
Fat, Necrosis	5 (83%)	4 (67%)	2 (67%)	3 (100%)	5 (100%)	3 (75%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:11

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Fibrosis			1 (33%)			
Pancreas	(46)	(44)	(47)	(45)	(48)	(44)
Acinar Cell, Atrophy	1 (2%)		1 (2%)		1 (2%)	1 (2%)
Acinar Cell, Vacuolization Cytoplasmic						
Angiectasis	2 (4%)					
Autolysis	2 (4%)	6 (14%)	2 (4%)	1 (2%)	1 (2%)	3 (7%)
Cyst						
Duct, Cyst						
Hemorrhage	1 (2%)					
Infiltration Cellular, Lymphocytic	8 (17%)	2 (5%)	11 (23%)	9 (20%)	7 (15%)	6 (14%)
Inflammation, Chronic						
Necrosis						
Salivary Glands	(46)	(48)	(48)	(47)	(48)	(47)
Atrophy						
Autolysis						
Fibrosis						
Hemorrhage						
Infiltration Cellular, Lymphocytic	33 (72%)	32 (67%)	33 (69%)	39 (83%)	37 (77%)	39 (83%)
Inflammation	1 (2%)					
Parenchym Cell, Hypertrophy						1 (2%)
Stomach	(0)	(0)	(0)	(0)	(7)	(0)
Stomach, Forestomach	(47)	(46)	(48)	(47)	(41)	(45)
Autolysis	2 (4%)	5 (11%)	2 (4%)	2 (4%)	1 (2%)	2 (4%)
Cyst Epithelial Inclusion						
Epithelium, Hyperplasia	8 (17%)	9 (20%)	4 (8%)	2 (4%)	10 (24%)	7 (16%)
Foreign Body	2 (4%)			1 (2%)	2 (5%)	
Hyperkeratosis		2 (4%)		1 (2%)	2 (5%)	5 (11%)
Infiltration Cellular, Lymphocytic						
Inflammation	2 (4%)	2 (4%)	2 (4%)	2 (4%)		
Ulcer					1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:11

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Ulcer					1 (2%)	1 (2%)
Stomach, Glandular	(47)	(45)	(48)	(46)	(40)	(45)
Autolysis	2 (4%)	5 (11%)	2 (4%)	2 (4%)	1 (3%)	2 (4%)
Cyst					1 (3%)	
Diverticulum						
Epithelium, Hyperplasia						
Epithelium, Hypertrophy						
Infiltration Cellular, Lymphocytic	1 (2%)					
Inflammation	1 (2%)					
Metaplasia, Squamous						1 (2%)
Mineralization		1 (2%)	1 (2%)		1 (3%)	2 (4%)
Thrombosis						
Tongue	(48)	(48)	(47)	(48)	(48)	(46)
Polyarteritis						
CARDIOVASCULAR SYSTEM						
Blood Vessel	(48)	(48)	(47)	(48)	(46)	(45)
Infiltration Cellular, Lymphocytic						
Inflammation						1 (2%)
Mineralization			1 (2%)			
Heart	(48)	(48)	(47)	(48)	(48)	(47)
Abscess						
Angiectasis	1 (2%)	4 (8%)			3 (6%)	4 (9%)
Artery, Hypertrophy						
Artery, Inflammation						
Atrium, Inflammation	1 (2%)					
Atrium, Thrombosis	1 (2%)					
Av Valve, Inflammation						
Cardiomyopathy	3 (6%)	2 (4%)			6 (13%)	2 (4%)
Embolus Tumor					1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:11

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Endothelium, Hyperplasia	3 (6%)	8 (17%)		1 (2%)	3 (6%)	14 (30%)
Epicardium, Inflammation, Chronic		1 (2%)			1 (2%)	2 (4%)
Mineralization	2 (4%)		2 (4%)	1 (2%)	2 (4%)	2 (4%)
Myocardium, Inflammation	2 (4%)	1 (2%)			1 (2%)	
Myocardium, Inflammation, Chronic						
Myocardium, Thrombosis	1 (2%)				1 (2%)	1 (2%)
Necrosis	1 (2%)					
ENDOCRINE SYSTEM						
Adrenal Gland	(0)	(1)	(0)	(0)	(2)	(0)
Parenchym Cell, Hyperplasia						
Adrenal Gland, Cortex	(46)	(44)	(46)	(46)	(45)	(46)
Accessory Adrenal Cortical Nodule						1 (2%)
Angiectasis	4 (9%)	2 (5%)	1 (2%)		1 (2%)	
Atrophy	1 (2%)					
Autolysis				1 (2%)		1 (2%)
Cyst		1 (2%)				
Hematopoietic Cell Proliferation	1 (2%)	1 (2%)				2 (4%)
Hemorrhage						1 (2%)
Hypertrophy						
Infarct						
Infiltration Cellular, Lymphocytic		1 (2%)				3 (7%)
Inflammation	1 (2%)					
Inflammation, Acute						1 (2%)
Pigmentation						1 (2%)
Subcapsular, Hyperplasia	35 (76%)	30 (68%)	36 (78%)	33 (72%)	37 (82%)	33 (72%)
Thrombosis						
Vacuolization Cytoplasmic			1 (2%)			
Adrenal Gland, Medulla	(45)	(41)	(44)	(44)	(38)	(46)
Angiectasis						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:11

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Autolysis				1 (2%)		1 (2%)
Hemorrhage						1 (2%)
Hyperplasia	1 (2%)		1 (2%)	2 (5%)		
Islets, Pancreatic	(46)	(44)	(47)	(45)	(48)	(44)
Autolysis	2 (4%)	4 (9%)	2 (4%)	1 (2%)	1 (2%)	2 (5%)
Hyperplasia	3 (7%)	4 (9%)	8 (17%)	2 (4%)	5 (10%)	4 (9%)
Infiltration Cellular, Lymphocytic Inflammation			1 (2%)			
Parathyroid Gland	(37)	(31)	(35)	(41)	(41)	(36)
Autolysis	1 (3%)			1 (2%)		
Cyst		1 (3%)			1 (2%)	
Infiltration Cellular, Lymphocytic Inflammation					1 (2%)	
Pituitary Gland	(41)	(38)	(40)	(41)	(40)	(38)
Angiectasis	2 (5%)		2 (5%)	1 (2%)	1 (3%)	1 (3%)
Cyst						
Hemorrhage		1 (3%)				
Pars Distalis, Hyperplasia	3 (7%)	1 (3%)	1 (3%)	3 (7%)	1 (3%)	1 (3%)
Thyroid Gland	(45)	(46)	(45)	(48)	(45)	(46)
Autolysis	1 (2%)			1 (2%)		1 (2%)
C Cell, Hyperplasia	1 (2%)				1 (2%)	
Cyst						1 (2%)
Cyst Multilocular	1 (2%)	1 (2%)			1 (2%)	
Depletion Secretory		1 (2%)				
Follicular Cel, Hyperplasia						
Infiltration Cellular, Lymphocytic	1 (2%)	1 (2%)		1 (2%)	1 (2%)	
Infiltration Cellular, Polymorphnuclr Inflammation						

GENERAL BODY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:12

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Tissue NOS	(1)	(0)	(0)	(1)	(0)	(2)
Abdominal, Cyst	1 (100%)					
Abdominal, Fat, Necrosis						1 (50%)
Abdominal, Inflammation	1 (100%)					
GENITAL SYSTEM						
Clitoral Gland	(34)	(40)	(38)	(41)	(41)	(35)
Atrophy	30 (88%)	37 (93%)	31 (82%)	36 (88%)	37 (90%)	29 (83%)
Autolysis		1 (3%)				
Dilatation					1 (2%)	
Infiltration Cellular, Lymphocytic			1 (3%)			
Pigmentation						
Ovary	(47)	(48)	(46)	(47)	(46)	(45)
Angiectasis	4 (9%)	6 (13%)		4 (9%)	4 (9%)	6 (13%)
Atrophy	37 (79%)	42 (88%)	33 (72%)	39 (83%)	37 (80%)	36 (80%)
Autolysis						
Congestion				1 (2%)		
Cyst	7 (15%)	4 (8%)	12 (26%)	12 (26%)	7 (15%)	6 (13%)
Hematocyst		2 (4%)	6 (13%)	1 (2%)		
Hemorrhage	2 (4%)				1 (2%)	
Hyperplasia, Tubular		5 (10%)			1 (2%)	4 (9%)
Infiltration Cellular, Histiocytic	1 (2%)		1 (2%)	1 (2%)		
Infiltration Cellular, Lymphocytic			1 (2%)		1 (2%)	
Inflammation						
Metaplasia, Osseous						
Mineralization	1 (2%)		2 (4%)	1 (2%)	1 (2%)	
Periovarn Tiss, Cyst		1 (2%)				2 (4%)
Periovarn Tiss, Infiltration Cellular, Lymphocytic	1 (2%)			1 (2%)		
Periovarn Tiss, Inflammation						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:12

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Periovarn Tiss, Thrombosis						
Pigmentation	1 (2%)		2 (4%)	1 (2%)		
Polyarteritis				1 (2%)		
Thrombosis			1 (2%)	1 (2%)	3 (7%)	3 (7%)
Uterus	(48)	(48)	(48)	(48)	(47)	(45)
Amyloid Deposition						
Angiectasis	7 (15%)	9 (19%)	4 (8%)	2 (4%)	8 (17%)	6 (13%)
Atrophy	1 (2%)					
Autolysis	1 (2%)					
Cervix, Hemorrhage	1 (2%)					
Dilatation						
Endometrium, Hyperplasia, Cystic	38 (79%)	33 (69%)	36 (75%)	38 (79%)	35 (74%)	31 (69%)
Hemorrhage	3 (6%)	1 (2%)			2 (4%)	
Infiltration Cellular, Histiocytic						
Infiltration Cellular, Polymorphnuclr						
Inflammation						
Inflammation, Suppurative		1 (2%)				
Mineralization						
Pigmentation						
Thrombosis	5 (10%)	6 (13%)	1 (2%)	2 (4%)	2 (4%)	4 (9%)
Vacuolization Cytoplasmic						
Vagina	(47)	(47)	(48)	(48)	(46)	(44)
Autolysis						
Exudate		1 (2%)		1 (2%)	1 (2%)	
Hemorrhage		1 (2%)				
Inflammation					1 (2%)	
Polyarteritis				1 (2%)		
HEMATOPOIETIC SYSTEM						
Bone Marrow	(48)	(48)	(48)	(46)	(48)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:12

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Angiectasis		2 (4%)				
Autolysis	1 (2%)	1 (2%)				3 (6%)
Infiltration Cellular, Histiocytic	1 (2%)					
Myeloid Cell, Hyperplasia	3 (6%)	6 (13%)	1 (2%)	2 (4%)	5 (10%)	12 (26%)
Pigmentation						
Lymph Node	(11)	(11)	(3)	(4)	(16)	(7)
Hematocyst			1 (33%)			
Lumbar, Autolysis						
Lumbar, Hematopoietic Cell Proliferation						1 (14%)
Lumbar, Hemorrhage	1 (9%)	1 (9%)			1 (6%)	
Lumbar, Hyperplasia	2 (18%)	2 (18%)		1 (25%)		
Lumbar, Infiltration Cellular, Histiocytic					1 (6%)	
Lumbar, Infiltration Cellular, Plasma Cell	1 (9%)					
Lumbar, Infiltration Cellular, Polymorphnuclr	1 (9%)	1 (9%)				
Lumbar, Inflammation					1 (6%)	
Mediastinal, Hyperplasia						
Pigmentation			1 (33%)			
Renal, Hematopoietic Cell Proliferation						1 (14%)
Renal, Hyperplasia		1 (9%)				1 (14%)
Renal, Infiltration Cellular, Polymorphnuclr						
Thoracic, Autolysis	1 (9%)					
Thoracic, Hyperplasia	2 (18%)					
Lymph Node, Mandibular	(43)	(46)	(48)	(46)	(38)	(47)
Atrophy						
Autolysis						1 (2%)
Hematopoietic Cell Proliferation						
Hemorrhage	1 (2%)					
Hyperplasia	4 (9%)	6 (13%)	5 (10%)	3 (7%)	4 (11%)	6 (13%)
Hyperplasia, Plasma Cell						
Infiltration Cellular, Histiocytic		2 (4%)				3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:12

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Infiltration Cellular, Histiocytic		2 (4%)				3 (6%)
Infiltration Cellular, Plasma Cell		1 (2%)				
Inflammation	1 (2%)					
Lymph Node, Mesenteric	(42)	(38)	(45)	(42)	(43)	(38)
Angiectasis	1 (2%)	2 (5%)	1 (2%)	1 (2%)		1 (3%)
Atrophy	1 (2%)	1 (3%)				1 (3%)
Autolysis	1 (2%)	2 (5%)	2 (4%)	1 (2%)		2 (5%)
Cyst						
Hematopoietic Cell Proliferation		1 (3%)				2 (5%)
Hemorrhage	1 (2%)	2 (5%)	1 (2%)			1 (3%)
Hyperplasia	1 (2%)		2 (4%)	3 (7%)	4 (9%)	4 (11%)
Infiltration Cellular, Histiocytic			1 (2%)			
Infiltration Cellular, Polymorphnuclr		1 (3%)				1 (3%)
Inflammation, Granulomatous						
Pigmentation	1 (2%)					
Spleen	(46)	(46)	(48)	(47)	(48)	(45)
Angiectasis		2 (4%)			1 (2%)	1 (2%)
Autolysis	1 (2%)	4 (9%)		2 (4%)	1 (2%)	2 (4%)
Capsule, Inflammation						
Hematopoietic Cell Proliferation	15 (33%)	25 (54%)	3 (6%)	10 (21%)	9 (19%)	29 (64%)
Hematopoietic Cell Proliferation Granulocytic						
Hemorrhage		1 (2%)			1 (2%)	
Infiltration Cellular, Histiocytic						
Lymph Follic, Hyperplasia	12 (26%)	5 (11%)	23 (48%)	19 (40%)	13 (27%)	5 (11%)
Pigmentation	1 (2%)	1 (2%)			1 (2%)	
Polyarteritis						
Red Pulp, Atrophy	1 (2%)					
Thrombosis		1 (2%)	1 (2%)			1 (2%)
Thymus	(34)	(36)	(39)	(38)	(43)	(39)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:12

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Atrophy	9 (26%)	15 (42%)	3 (8%)	10 (26%)	8 (19%)	14 (36%)
Autolysis	2 (6%)	2 (6%)	1 (3%)	1 (3%)		3 (8%)
Cyst				1 (3%)		
Hemorrhage				1 (3%)		
Hyperplasia	3 (9%)	2 (6%)	4 (10%)	3 (8%)	3 (7%)	1 (3%)
INTEGUMENTARY SYSTEM						
Mammary Gland	(48)	(47)	(47)	(48)	(48)	(45)
Autolysis	1 (2%)		1 (2%)	1 (2%)		
Duct, Ectasia	1 (2%)					
Hyperplasia	2 (4%)	2 (4%)	4 (9%)	3 (6%)	2 (4%)	2 (4%)
Infiltration Cellular, Lymphocytic		1 (2%)				2 (4%)
Lactation	6 (13%)	3 (6%)	4 (9%)		4 (8%)	1 (2%)
Skin	(48)	(47)	(48)	(48)	(48)	(47)
Autolysis	1 (2%)		1 (2%)	1 (2%)		2 (4%)
Cyst Epithelial Inclusion		1 (2%)				
Fat, Necrosis					1 (2%)	
Fibrosis						
Hemorrhage						
Inflammation		1 (2%)				
Inflammation, Chronic					1 (2%)	
Neovascularization						
Sebaceous GI, Distended					1 (2%)	
Thrombosis						
Ulcer	1 (2%)					
MUSCULOSKELETAL SYSTEM						
Bone	(48)	(48)	(48)	(48)	(48)	(47)
Cartilage, Sternum, Degeneration						
Femur, Angiectasis						
Femur, Fibrous Osteodystrophy	3 (6%)	1 (2%)	1 (2%)	7 (15%)	3 (6%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:13

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Sternum, Angiectasis						
Sternum, Autolysis	1 (2%)					
Sternum, Fibrous Osteodystrophy	15 (31%)	4 (8%)	15 (31%)	18 (38%)	12 (25%)	3 (6%)
Skeletal Muscle	(48)	(48)	(48)	(48)	(48)	(47)
Autolysis						
Degeneration		1 (2%)		1 (2%)		
Diaphragm, Hyperplasia						
Infiltration Cellular, Lymphocytic					1 (2%)	1 (2%)
Mineralization		1 (2%)				
NERVOUS SYSTEM						
Brain	(0)	(0)	(0)	(0)	(4)	(0)
Brain, Brain Stem	(0)	(0)	(0)	(0)	(1)	(0)
Hemorrhage					1 (100%)	
Brain, Cerebellum	(47)	(48)	(48)	(48)	(40)	(47)
Abscess		1 (2%)				
Autolysis	1 (2%)					
Hemorrhage				1 (2%)	2 (5%)	1 (2%)
Meninges, Inflammation, Chronic Active						
Thalamus, Mineralization						
Brain, Cerebrum	(47)	(48)	(48)	(48)	(44)	(47)
Autolysis	1 (2%)					
Granuloma						
Hemorrhage	1 (2%)			1 (2%)	2 (5%)	2 (4%)
Hypothalamus, Compression						
Inflammation						1 (2%)
Meninges, Inflammation					1 (2%)	
Meninges, Inflammation, Chronic Active						
Necrosis						1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

Test Type: CHRONIC

Route: DOSED WATER

Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Urethane + ethanol (combination)

CAS Number: URETHCOMB

Date Report Requested: 10/18/2014

Time Report Requested: 00:13:13

First Dose M/F: NA / NA

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Perivascular, Infiltration Cellular, Lymphocytic					1 (2%)	
Thalamus, Mineralization	23 (49%)	18 (38%)	29 (60%)	28 (58%)	26 (59%)	28 (60%)
Peripheral Nerve Autolysis	(48)	(48)	(48)	(48)	(48)	(47)
Spinal Cord	(0)	(0)	(0)	(0)	(8)	(0)
Spinal Cord, Thoracic Autolysis	(47)	(48)	(48)	(48)	(40)	(47)
Hemorrhage		1 (2%)		1 (2%)		1 (2%)
RESPIRATORY SYSTEM						
Larynx	(47)	(46)	(45)	(47)	(47)	(47)
Autolysis	1 (2%)			1 (2%)		
Hemorrhage	1 (2%)					
Inflammation	1 (2%)					
Lung	(48)	(48)	(48)	(48)	(48)	(48)
Alveolar Epith, Hyperplasia	5 (10%)	3 (6%)		4 (8%)	3 (6%)	6 (13%)
Alveolus, Exudate		1 (2%)				
Arteriole, Hypertrophy			1 (2%)			
Autolysis						
Congestion						
Crystals						
Hemorrhage	2 (4%)	1 (2%)	3 (6%)	6 (13%)	4 (8%)	4 (8%)
Infiltration Cellular, Histiocytic	2 (4%)	9 (19%)	1 (2%)	3 (6%)	5 (10%)	6 (13%)
Infiltration Cellular, Lymphocytic	25 (52%)	16 (33%)	27 (56%)	22 (46%)	19 (40%)	21 (44%)
Inflammation, Chronic Active				1 (2%)		
Inflammation, Suppurative	1 (2%)					
Leukocytosis						2 (4%)
Pigmentation						
Nose	(48)	(48)	(47)	(48)	(48)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:13

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Autolysis						
Fibrous Osteodystrophy						
Hemorrhage	1 (2%)					
Inflammation		1 (2%)				
Trachea	(46)	(47)	(47)	(48)	(47)	(45)
Autolysis	1 (2%)			1 (2%)		
Glands, Ectasia						1 (2%)
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(1)	(0)
Eye	(48)	(46)	(48)	(48)	(47)	(45)
Atrophy		3 (7%)				5 (11%)
Autolysis			2 (4%)			1 (2%)
Bilateral, Phthisis Bulbi						
Cornea, Inflammation	4 (8%)	8 (17%)	2 (4%)	6 (13%)	3 (6%)	4 (9%)
Hemorrhage	1 (2%)					
Infiltration Cellular, Lymphocytic	1 (2%)					
Lens, Cataract		3 (7%)		1 (2%)	1 (2%)	1 (2%)
Phthisis Bulbi		1 (2%)			1 (2%)	1 (2%)
Harderian Gland	(46)	(47)	(48)	(48)	(46)	(46)
Atrophy						
Autolysis						1 (2%)
Dilatation						
Hyperplasia	1 (2%)	2 (4%)				3 (7%)
Infiltration Cellular, Lymphocytic	9 (20%)	1 (2%)	7 (15%)	3 (6%)	8 (17%)	3 (7%)
Inflammation		1 (2%)			1 (2%)	
Inflammation, Chronic						1 (2%)
Necrosis						
Lacrimal Gland	(44)	(43)	(45)	(45)	(45)	(43)
Atrophy	3 (7%)	2 (5%)	3 (7%)	6 (13%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Date Report Requested: 10/18/2014

Test Type: CHRONIC

Test Compound: Urethane + ethanol (combination)

Time Report Requested: 00:13:13

Route: DOSED WATER

CAS Number: URETHCOMB

First Dose M/F: NA / NA

Species/Strain: Mouse/B6C3F1/NCTR

Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Autolysis						
Cyst						
Duct, Dilatation	1 (2%)	1 (2%)	3 (7%)	2 (4%)	1 (2%)	
Hemorrhage						
Infiltration Cellular, Lymphocytic	27 (61%)	20 (47%)	25 (56%)	25 (56%)	25 (56%)	26 (60%)
Inflammation	1 (2%)					
Parenchym Cell, Hypertrophy						
Vacuolization Cytoplasmic						
Zymbal's Gland	(41)	(44)	(48)	(46)	(43)	(40)
Atrophy					1 (2%)	
Autolysis						
Hyperplasia						
Infiltration Cellular, Lymphocytic						1 (3%)
Inflammation, Chronic						
URINARY SYSTEM						
Kidney	(48)	(48)	(48)	(48)	(48)	(47)
Accumulation, Hyaline Droplet		1 (2%)	1 (2%)	2 (4%)	3 (6%)	3 (6%)
Amyloid Deposition		1 (2%)				1 (2%)
Autolysis	2 (4%)			2 (4%)	1 (2%)	
Casts					1 (2%)	1 (2%)
Congestion						
Cyst				1 (2%)		
Embolus Bacterial						
Glomerulosclerosis	2 (4%)	3 (6%)	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Hematopoietic Cell Proliferation						1 (2%)
Hydronephrosis		2 (4%)	1 (2%)			
Infarct	1 (2%)		3 (6%)			
Infiltration Cellular, Lymphocytic	20 (42%)	11 (23%)	19 (40%)	21 (44%)	18 (38%)	24 (51%)
Infiltration Cellular, Plasma Cell	1 (2%)	1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 00602-05
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: Mouse/B6C3F1/NCTR

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Urethane + ethanol (combination)
CAS Number: URETHCOMB

Date Report Requested: 10/18/2014
Time Report Requested: 00:13:13
First Dose M/F: NA / NA
Lab: NCTR

B6C3F1/NCTR Mouse FEMALE	2.5%ETH/30PPMUR E	2.5%ETH/90PPMUR E	5.0%ETH/0PPM URE	5.0%ETH/10PPMUR E	5.0%ETH/30PPMUR E	5.0%ETH/90PPMUR E
Infiltration Cellular, Polymorphnuclr Inflammation						
Metaplasia, Osseous		1 (2%)	1 (2%)			
Mineralization		1 (2%)	1 (2%)		1 (2%)	2 (4%)
Nephropathy		1 (2%)		1 (2%)	1 (2%)	
Papilla, Necrosis					1 (2%)	
Polyarteritis						
Regeneration		1 (2%)				
Renal Tubule, Atrophy						
Renal Tubule, Degeneration, Focal						
Renal Tubule, Pigmentation				1 (2%)		
Urinary Bladder	(47)	(45)	(46)	(46)	(47)	(45)
Autolysis	1 (2%)	3 (7%)	2 (4%)	3 (7%)		4 (9%)
Distended						
Fibrosis						1 (2%)
Infiltration Cellular, Lymphocytic	27 (57%)	19 (42%)	25 (54%)	22 (48%)	23 (49%)	17 (38%)
Polyarteritis				1 (2%)		
Ulcer						1 (2%)

**** END OF REPORT ****